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ABSTRACT 
 
Background. Several studies demonstrate that immune inflammation and trafficking of 
immune cells to affected tissues plays a major role in the pathogenesis of tuberculosis (TB) 
and human immunodeficiency virus (HIV) infections; however, characterization of soluble 
markers of lymphocyte trafficking and inflammation in the context of TB and TB/HIV co-
infection remains to be elucidated. Here we sought to evaluate the role of specific 
lymphocyte trafficking and inflammatory markers as predictors of TB disease.  
Methods. The presented study was performed on stored plasma samples from TB Recurrence 
upon Treatment with HAART (TRuTH) and Improving Recurrence Success (IMPRESS) 
cohorts. TB recurrent cases (n = 37) were matched to controls (n = 103) on study arm in the 
original trial and antiretroviral therapy (ART) start date. A subset of cases was followed 
longitudinally at: preTB, active TB and postTB/cure timepoints. In IMPRESS a subset of 
HIV infected (n = 41) and HIV uninfected (n = 37) individuals were sampled at active TB 
disease and post TB/cure. Plasma concentrations of soluble mucosal addressin cell adhesion 
molecule (sMAdCAM), soluble intracellular adhesion molecule (sICAM), soluble vascular 
adhesion molecule (sVCAM), lipopolysaccharide binding protein (LBP) and transforming 
growth factor – beta (TGF-β) were measured using enzyme-linked immunosorbent assays 
(ELISAs) and Multiplex assays.  
Results.  Two analytes were associated with increased rate of TB recurrence in the univariate 
model: square root transformed (sqrt) sICAM (odds ratio [OR] 1.047. 95% confidence 
interval [CI] 1.014 – 1.081, p = 0.005) and sqrtLBP (OR 3.283, 95% CI 1.018 – 10.588, p = 
0.047) and the multivariable model. Longitudinal analysis showed reduced levels of LBP, 
21 
 
sMAdCAM and sVCAM and an increase in levels of TGF- β3 during the entire follow-up. In 
IMPRESS data, trends of increased plasma LBP from active TB to post TB/cure in HIV 
infected individuals and trends of reduced plasma LBP in HIV uninfected individuals post 
treatment were observed. 
Conclusion. The TRuTH data demonstrates that plasma levels of sICAM and LBP can act as 
predictors of TB recurrence in HIV infected individuals receiving ART treatment. A decrease 
of plasma LBP levels from active TB to treatment completion in HIV uninfected individuals 
likely suggests that active TB and associated inflammatory changes are associated with gut 
inflammation and dysbiosis. 
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CHAPTER 1. Literature Review 
 
1.1 TB Epidemic  
Globally,  the burden of Tuberculosis (TB) remains high even though the incidence rate is 
decreasing at 2% per annum (WHO, 2013). TB disease is established largely in the lungs 
(pulmonary), however the bacterium can spread to different organs (called extra pulmonary 
TB) (Harisinghani et al., 2000, O'Garra et al., 2013, WHO, 2016b). Despite being a 
preventable and treatable disease, TB is currently ranked as the ninth leading cause of 
mortality globally and ranks above human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) as the primary cause of mortality from an 
infectious agent, especially in low/middle income countries (Figure 1) (WHO, 2017). 
Globally in 2017, an estimated 1.3 million deaths occurred among HIV uninfected 
individuals. Additionally, 300 000 deaths occurred in HIV infected individuals who had TB.  
Among the estimated number of cases, 90% were adults and of this, 65% were male (WHO, 
2017, Facts, 2017).  
 
The highest rate of the TB burden is found in sub-Saharan Africa, where the HIV epidemic is 
the greatest (Zumla et al., 2013, WHO, 2017). According to WHO, TB is responsible for 
aloss of 25,000 lives (excluding deaths due to co-infections) and an estimated 450,000 active 
cases a year in SA (Facts, 2017, WHO, 2016a). KwaZulu-Natal (KZN), one of the nine 
provinces in SA, has been burdened with the highest incidence of TB, followed by the 
Eastern Cape and Western Cape respectively. However, due to better screening and 
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treatment, KZN has shown a steady decline of TB incidence from 1185 to 685 per 100 000 
population in the last five years  (Facts, 2017).  
Figure 1. Global estimates of TB incidence in 2016 1 
1Adapted from (WHO, 2017), accessed on January 2018. 
 
1.1.2. TB spectrum of disease  
TB is caused by infection with Mycobacterium tuberculosis (M.tb), an acid – fast bacilli 
(AFB). The bacterium is spread predominantly through acts of coughing and sneezing and is 
a common cause of pulmonary TB (Algood et al., 2003). M.tb is an effective intracellular 
pathogen (Van Crevel et al., 2002) belonging to the Mycobacteriaceae family. It is an 
aerobic, non-motile organism, called a tubercle bacilli (rod shapped) (Knechel, 2009). 
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When an individual inhales the M.tb bacterium, the primary innate immune cells that 
encounter the infection are the alveolar macrophages (Behler et al., 2012). Once bacterial 
dissemination occurs, T cell priming takes place and triggers the expansion of antigen 
specific T cells, which are later recruited to the lungs (Nunes-Alves et al., 2014). The 
recruitment of T cells, B cells, macrophages and other leukocytes leads to the formation of 
granulomas, which can contain M.tb. However, in some individuals the granuloma is 
unsuccessful in enclosing the infection when the bacterial load is abundant. This allows for 
dissemination of the bacteria to other organs, where the M.tb can re-enter the respiratory tract 
or the bloodstream.  
 
Although TB is an ancient disease, latent TB infection (LTBI) was only recognized at the end 
of the 19th century (Muñoz et al., 2015). The asymptomatic individuals develop immune 
responses to M.tb, but do not present clinical evidence of active TB (Getahun et al., 2015, 
Ernst, 2012). There are approximately 2 billion cases of LTBI, and 9 million cases of active 
TB (WHO, 2018a). LTBI has been known to transition into active disease (known as 
reactivation). Reactivation occurs in a 5-15% of latently infected individuals, predominantly 
in the first 5 years of active infection. Individuals who have LTBI are characterised as 
important reservoirs for new cases of active TB (Getahun et al., 2015, Kiazyk and Ball, 
2017). Both bacterial and environmental factors have been found to play a role in LTBI 
reactivation, however, the exact mechanism is not fully understood. Active infection leads to 
clinical symptoms such as weight loss, fever and persistent coughing and is clinically known 
as active TB (Dheda et al., 2010, O'Garra et al., 2013, Harisinghani et al., 2000). Active TB 
disease can arise after a new infection or after the reactivation of a latent form and it can be 
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diagnosed by the detection of the M.tb in tissue culture and sputum samples (O'Garra et al., 
2013, Lin and Flynn, 2010).  
 
The spectrum of TB is diverse and recent research has shown that there is a continuous 
spectrum of metabolic bacterial activity and antagonistic immunological responses during 
transition from LTBI to active TB disease. Due to these findings, Drain et al has recently 
proposed the addition of two clinical states in the spectrum; (i) incipient TB and (ii) 
subclinical TB. Incipient TB infection is defined as an infection that has viable M.tb and is 
likely to advance to active TB disease without further intervention. These individuals do not 
have signs of active TB disease such as clinical symptoms and radiographic abnormalities. 
Subclinical TB disease is defined as disease caused by viable M.tb and does not cause clinical 
TB symptoms, however abnormalities related to active TB can be detected by radiologic and 
microbiologic assays (Achkar and Jenny-Avital, 2011, Drain et al., 2018). 
 
1.1.3. TB diagnosis, management and treatment 
There are four methods by which active TB can be detected; these tests include chest X-ray/ 
PET-CT, sputum smears (microscopy), molecular and culture based tests (Pai et al., 2016). 
Microbiologic demonstration of AFB is the mainstay of diagnosis of M.tb infection.  For 
more than a century, diagnosis of TB has been conducted by light microscopy on sputum 
smears (Lawn, 2015). Compared to other diagnostic tools, it is fairly quick and uses 
inexpensive materials (Lawn, 2015). However, there are limitations with this technique such 
as: (i) it has low sensitivity and requires a lot of manpower to examine and analyse resulting 
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in variability and (ii) the sputum sensitivity is limited to the amount of bacilli in the sample 
(Lawn, 2015, Gupta et al., 2013).  
 
The presence of M.tb can also be determined in clinical specimens using solid and liquid 
cultures. A number of culture media such as: (i) Lowenstein – Jensen (LJ) and (ii) 
Middlebrook 7H10/11 and (iii) Middlebrook 7H9 have been used to isolate and detect the 
presence of M.tb (SAITO, 1998). The disadvantage of using a culture based method is the 
turn over time; it takes 3-6 weeks for M.tb growth and isolation (Naveen and PeeraPur, 
2012). Liquid media have been associated with shorter detection time and higher recovery of 
tubercle bacilli. Culture based assays such as the BD BACTECTM – mycobacterium growth 
indicator tubes (MGIT) have improved the time to detection of M.tb (Naveen and PeeraPur, 
2012).  
 
Since 2010, a molecular assay based on the GeneXpert technology known as Xpert MTB/RIF 
has been used to diagnose TB and detect resistance to rifampicin (Albert et al., 2016, WHO, 
2014, Pai et al., 2016). This molecular assay provides a greater precision than the sputum 
smear and therefore, the Xpert MTB/RIF is provisionally recommended as the first line 
diagnostic test used in presumed cases of active TB (children and adults) (Steingart et al., 
2013, Boehme et al., 2010, Boehme et al., 2011, Detjen et al., 2015). Currently the WHO 
encourages the use of the Xpert MTB/RIF with patients who are HIV infected and who are 
suspected of having active TB, since sputum smears can only detect around 43% of these 
patients (Getahun et al., 2007).   
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LTBI has no gold standard diagnostic test; however there are two tests to detect the presence 
of M.tb: the tuberculin skin test (TST) and the interferon gamma release assay (IGRA). The 
TST is based on a delayed hypersensitivity reaction which occurs when M.tb infected 
individuals are exposed to a mixture of antigens known as purified protein derivative (PPD). 
This results in a  skin reaction that can be interpreted as a positive or a negative result 
(Huebner et al., 1992). Although the TST is advantageous mostly in resource limited  
settings, it has major disadvantages such as: limited predictive value and the specificity of the 
test can be compromised by the Bacillus Calmette-Guérin (BCG) vaccination (Pai et al., 
2016). The IGRA test is a blood test, which measures the release of IFNγ from T cells 
following stimulation by early secreted antigenic target 6 (ESAT-6) and culture filtrate 
protein 10 (CFP-10) that are specific to the M.tb complex (Mahairas et al., 1996, Sørensen et 
al., 1995). However the IGRA test also provides poor predictive values (Rangaka et al., 2012, 
Pai et al., 2014, Pai et al., 2016). 
 
Treatment of active, drug sensitive TB in children (>8years and > 30kgs) and adults are 
separated into two phases. In the first phase (intensive phase) patients are given rifampicin 
(RMP), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB) for 2 months. This 
helps to decrease the amount of infectious bacilli in the patients, which can be observed 
between 10-14 days from the start of treatment(Directorate, 2014, WHO, 2010). Thereafter, 
INH and RMP are administered for an additional 4 months to eliminate remaining bacilli, 
known as the continuation phase (second phase). These drugs are given in combination for no 
less than 6 months and no more than 9 months (Nahid et al., 2016, WHO, 2010). 
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Currently the BCG vaccine is the only approved vaccine used to prevent active TB. The 
efficiency of the BCG vaccine against adult pulmonary cases conducted in clinical trials 
ranges between 0-80%, and it is currently not known why there is so much inconsistency in 
BCG vaccine efficacy, although phenotypic and genotypic differences between BCG strains 
are thought to be one of the main contributors (Mangtani et al., 2013, Roy et al., 2014, Pai et 
al., 2016). Studies conducted on infants and children (<5 years) have shown that the 
effectiveness of the vaccine in the protection against TB ranges from 50-80%. In infants (<5 
years), the vaccine is vital in preventing active TB and reducing morbidity and mortality rates 
(Barreto et al., 2011, Pai et al., 2016).  
 
1.2. HIV Epidemic 
Since the first documentation of the acquired immunodeficiency syndrome (AIDS) in the 
1980’s, HIV has claimed more than 35 million lives (UNAIDS, 2016). HIV infection is 
characterised by: (i) the progressive depletion of CD4+ T cells, (ii) chronic immune 
activation and immune exhaustion and (iii) subsequent opportunistic infections (Maartens et 
al., 2014). 
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Approximately 36.9 million individuals of all ages have been reported to be living with HIV 
and almost 1.8 million individuals have acquired new HIV infections worldwide in 2017 
(Figure 2) (UNAIDS, 2018). There are approximately 19 million HIV infected individuals in 
Africa, of which an estimated 7.2 million individuals are infected and living in SA (UNAIDS, 
2018). Women between the ages of 15 and 24 compared to the opposite sex, have an eight 
time greater risk of  HIV and acquire HIV at least 7 years earlier than men (Zuma et al., 
2016, Karim et al., 2015). A study conducted in KZN looked at transmission networks and 
the risk of HIV infection; this study found that a key factor that influences HIV incidence is 
the age-disparate relationships between younger women and older men (De Oliveira et al., 
2017). Therefore, future prevention strategies in SA need to address sexual partnering in 
combination with treatment. 
Figure 2. Global Prevalence of HIV in adults in 2016 2 
2Adapted from (UNAIDS, 2017) 
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1.2.1. HIV treatment and prevention 
In the late 1990’s, combination antiretroviral therapy (ART) regimens were developed, which 
transformed HIV from a progressive illness to a manageable chronic disease by supressing 
viral replication (Maartens et al., 2014). The development of ART has been a key 
accomplishment in the fight against HIV, however ART is not able to eliminate the infection 
(Volberding and Deeks, 2010, Simon et al., 2006). With the current ‘test and treat’ strategy, 
ART is initiated after diagnosis is made irrespective of the CD4 cell count. In the hope of 
preventing HIV, oral pre-exposure prophylaxis (PrEP) is given to individuals who are at high 
risk for HIV infection.  PrEP is a combination of tenofovir (TDF) and emtricitabine (FTC) 
and in clinical trials it has shown to reduce the risk of sexual acquisition in HIV-
serodiscordant couples and in men who have sex with men (Eakle et al., 2017, Grant et al., 
2010). 
 
The quest for an effective HIV vaccine has been on-going for many years however, there has 
not been a clinical trial which has shown a vaccine that is adequately protective (Whaley and 
Mayer, 2014). The RV144 trial that was conducted between 2003 and 2006 on HIV 
uninfected Thai individuals, administered a vaccine containing a prime and boost regimen, 
which consisted of a mixture of the canarypox virus, ALVAC-HIV (prime) and AIDSVAX 
B/E gp120 (boost) (Bekker and Gray, 2017, Whaley and Mayer, 2014). The combined  
vaccine resulted in a 31.2% effectiveness in the modified intent to treat population, thus 
resulting in the first vaccine to show promising efficacy in decreasing HIV acquisition 
(Bekker and Gray, 2017, Whaley and Mayer, 2014). The HVTN 097 study in SA replicated 
the RV144 trial by looking at HIV subtype C. This study showed similar results to the RV144 
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study irrespective of the route of transmission, HIV subtype and ethnicity of the study 
population (Gray et al., 2014, Bekker and Gray, 2017). 
 
1.3. TB/HIV Co-infection 
The leading cause of death in people infected with HIV is the co-infection with M.tb (Bell 
and Noursadeghi, 2018, Pawlowski et al., 2012, Sutherland et al., 2014) and the risk of active 
TB increases substantially when HIV infection alters the course of M.tb infection (Bell and 
Noursadeghi, 2018). The epidemics of TB and HIV are closely related, such that the risk of 
acquiring TB in people living with HIV (PLHIV) is between 16 and 27 times greater than 
people living without HIV infection (WHO, 2018b). WHO reported that there had been 10.4 
million cases of TB and from these estimates approximately 1.2 million cases were people 
who had HIV (WHO, 2017).  
 
1.3.1. TB/HIV Epidemic in South Africa  
The overlap between HIV and TB epidemics is greatest in sub-Saharan Africa, with more 
than 50% of TB individuals being co-infected with HIV (WHO, 2007). SA is ranked in the 
top five countries globally with respect to TB incidence and it ranks first in the number of 
cases of TB/HIV co-infection, with approximately 65% of TB individuals dually co-infected 
with HIV (WHO, 2013).  
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1.3.2. Difficulty in diagnosing TB in HIV infected individuals  
There has been a dire need to improve TB diagnoses in sub-Saharan Africa (Kaforou et al., 
2013). Diagnostic tests for active TB have been challenging in co-infected individuals since 
sputum of HIV infected individuals have less bacilli than that of HIV uninfected individuals 
(Getahun et al., 2010). HIV infection is known to compromise the TB diagnostic test strength 
and efficacy (Getahun et al., 2011). Presently, there is no internationally recognized tool to 
screen for TB in individuals who are living with HIV (Getahun et al., 2011). TB diagnostic 
tests such as smear microscopy and the chest radiography yield poor results in PLHIV. The 
recommended test for TB in individuals who are infected with HIV is the GeneXpert, 
however mycobacterial cultures remain the gold standard for diagnosis (Getahun et al., 2010, 
WHO, 2018a). The complexities of accurately characterizing TB in HIV infected individuals 
highlights the need for research to identify novel biomarkers that can accurately diagnose or 
predict TB in HIV infected individuals, as this is crucial for timely management of co-
infection. 
 
1.3.3. Effect of ART on TB 
Mortality remains high in individuals that have severe immunosuppression, regardless of 
effective TB treatment (Kyeyune et al., 2010, Koenig et al., 2009). The mortality rate of HIV 
infected individuals is reported to be around 30% in the first 2 months of TB treatment if 
ART is held back (Blanc et al., 2011). Previous studies have argued both for and against 
delaying ART initiation (Blanc et al., 2011). The “Starting Antiretroviral Therapy at Three 
Points in Tuberculosis” (SAPiT) study, showed that the initiation of ART during TB 
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treatment improved survival by 56% in HIV-TB co-infected individuals with < 500 per cubic 
millimeter CD4+ T cell count (Abdool Karim et al., 2010).  
 
Another complication of ART in TB patients, in resource limited settings is the immune 
reconstitution inflammatory syndrome (IRIS). IRIS is a highly recognized phenomenon, 
through which ART is hindered (French et al., 2004, Hamill, 2003). It is as a result of rapid 
restoration of pathogen specific immune responses to an opportunistic infection and as a 
result, causes the deterioration of a treated infection or a new presentation of an existing 
subclinical infection. Typically IRIS occurs during the start of ART and has been associated 
with a wide range of pathogens, including mycobacteria (Hamill, 2003, French et al., 2004, 
Lawn et al., 2005a). 
 
The burden of TB/HIV co-infection is high in low income and middle income settings. 
Therefore, patients that enter ART programmes are currently diagnosed with TB or later 
develop TB after the initiation of ART (Corbett et al., 2003). A study conducted in SA 
showed that 25% of patients who attended a community based ART programme, received TB 
treatment at ART initiation. In the first year of ART treatment, the incidence of TB was 13.4 
cases per 100 persons per year (Lawn et al., 2006). Approximately one third of patients with 
TB/HIV co-infection that initiate ART in these settings are more likely to develop TB-
associated IRIS (TB-IRIS) (Lawn et al., 2005a), which is considered a major clinical 
challenge in countries that are resource limited (Colebunders et al., 2006, Kumarasamy et al., 
2004, Manosuthi et al., 2006, Lawn et al., 2007). TB-IRIS is defined as an excessive immune 
response against M.tb that can occur in both HIV infected or HIV uninfected patients, who 
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are on or have completed TB treatment. In patients who are HIV infected, TB-IRIS occurs 
after the initiation of ART, independent of HIV viremia suppression. There are two forms of 
IRIS: (i) paradoxical IRIS, where a treated patient has a new or worsening symptom or has a 
recurrent episode, and (ii) unmasking IRIS, is an ART associated inflammatory manifestation 
of a subclinical infection (Meintjes et al., 2008, Lanzafame and Vento, 2016, Michailidis et 
al., 2005). Currently, the immunopathogenesis remains largely unknown. There is no 
diagnostic test for IRIS or TB-IRIS, therefore confirmation relies on case definition that 
include laboratory and clinical data (Lanzafame and Vento, 2016). 
 
1.4. Brief overview of the immune response  
 
1.4.1 Innate Immune Response 
The innate immune response is nonspecific and is made up of a number of cells such as: 
macrophages, monocytes, neutrophils, natural killer (NK) cells and dendritic cells (DCs).  
Phagocytic cells such as macrophages, monocytes, neutrophils and DCs are important in 
engulfing and removing the infected cells and pathogens. Macrophages are the first cells to 
recognize a pathogen; these cells then engulf the pathogen and initiate an inflammatory 
response. This results in the expression of the major histocompatibility complex (MHC) class 
II molecule on the surface of the cell, which allows the macrophage to present peptides of the 
processed pathogen to T lymphocytes (Fraser et al., 1998, Aderem and Underhill, 1999). 
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Clearing of microbial components is accomplished by neutrophils which also have the ability 
to repair tissue. DCs are known as highly specialised phagocytes and have the ability to 
present engulfed antigens on their cell surface through the MHC molecules. These are then 
recognized by T cells inducing an adaptive immune response. T cells, when activated are able 
to produce cytokines that can activate inflammatory responses, such as type I interferons 
(IFNs) (Bell et al., 1999, Altfeld et al., 2011). NK cells play a key role in an initial immune 
response to infections and are activated by IFNs and other cytokines derived from 
macrophages. These cells interact with MHC class I molecules, through inhibitory and 
activating receptors. NK cells are able to differentiate between cells that are infected and 
uninfected by inhibitory receptors, thus conferring self-tolerance and permitting toxicity 
towards impaired cells (Caligiuri, 2008, Vivier et al., 2008, Campbell and Hasegawa, 2013).   
 
1.4.2 Adaptive Immune response 
The adaptive immune response is mediated by T and B cell responses. In the lymphoid 
tissues the antigens are presented to the T cells by the MHC molecules. Activation of T cells 
initiates production of interleukin (IL)-2, which mediates T cell proliferation and 
differentiation into effector T cells.  
 
MHC class I molecules carry antigens which are presented to the CD8+ T cells, classified as 
cytotoxic T lymphocytes (CTL) able to eliminate infected cells (Janeway Jr and Medzhitov, 
2002, Santana and Esquivel‐Guadarrama, 2006, Paranjape, 2005). MHC class II molecules 
present antigens to CD4+ T cells. CD4+ T cells can differentiate into T helper cell subsets 
(Th), such as: (i) T helper 1 (Th1), (ii) T helper 2 (Th2), (iii) T helper 17 (Th17) and (iv) T 
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regulatory (Treg) cells. IFN-γ and tumour necrosis factor-α (TNF-α) cytokines, which aid the 
protection against intracellular pathogens are mainly produced by Th1 cells (Chaplin, 2010). 
On the other hand, Th2 cells are able to stimulate the production of antibodies and cytokines 
such as IL-4, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF), which 
are vital in producing an immune response to extracellular infections (Zheng and Flavell, 
1997). The Th17 cells produce pro-inflammatory IL-17 and IL-22 cytokines, while tolerance 
for self-antigens is maintained by Treg cells  (Weaver et al., 2006, Sehrawat and Rouse, 
2017). 
 
Antigen specific antibodies are secreted by B cells against antigens which are presented to 
lymphocytes by APCs. Activation and differentiation of B cells is supported through Th2 
helper cells. In adaptive immunity, antibodies contribute in many different ways: i) 
neutralising antibodies are able to prevent pathogens from entering the cell by binding to the 
pathogen, ii) phagocytosis is also enhanced by the coating of antibodies to the surface of the 
pathogen, which is recognized by the Fc receptors on the phagocytic cells or iii) by activating 
the complement system (Moir and Fauci, 2009, Haynes et al., 2011).  
 
1.5 Lymphocyte trafficking  
Recruitment of leukocytes plays a major role during the host immune response to an 
infection. The process of lymphocyte trafficking comprises of a complex cascade from the 
blood into inflamed tissues, where each stage of the cascade is controlled by molecules such 
as chemokines and adhesion molecules (Bromley et al., 2008, Abram and Lowell, 2009). 
This complex cascade occurs between leukocytes and the endothelium and includes 
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leukocyte rolling, tethering, firm adhesion, crawling and transendothelial migration. During 
lymphocyte trafficking there are two classes of molecules known as integrins and selectins 
with their respective ligands, that are known to aid in the adhesion of vascular endothelial 
cells and the circulation of leukocytes  (Kinashi, 2005, Bromley et al., 2008).  
 
Integrins are cell surface receptors composed of alpha (α) and beta (β) chain heterodimers 
(Kinashi, 2005, Hynes, 1992). The heterodimer chain can be divided into integrin subfamilies 
based on their β chain such as: β1, β2, and β4 (Imhof and Dunon, 1995). Integrins have 
essential roles in the host immune system, which include: (i) attachment of leukocyte to 
endothelial cells and APCs (ii) cytotoxic killing and (iii) extravasation of cells into tissues.  
 
Trafficking of lymphocyte to tissues during inflammatory responses involves a sequence of 
complexed mechanisms which include: adhesion molecules and tissue based chemokine 
production. In this study we will assess the role of three adhesion molecules in TB disease: 
intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) 
and mucosal addressin cell adhesion molecule 1 (MAdCAM-1). 
 
ICAM-1 binds lymphocyte function-associated antigen 1 (LFA-1) expressed on neutrophils 
and is constitutively conveyed on certain cell types such as: endothelial cells, epithelial cells 
and DCs (Dustin et al., 1986). ICAM-1 was found to be significant in leukocyte-endothelial 
interaction as well as in the interaction of T cells with APCs (Abram and Lowell, 2009). 
VCAM-1 is expressed in the central nervous system, bone marrow and skin where it binds to 
very late antigen-4 (VLA-4), a member of alpha-4-beta-1 (α4β1) integrin family, expressed 
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on most leukocytes except neutrophils. VCAM-1 can be expressed by endothelial cells and its 
expression can be induced by HIV (Osborn et al., 1989). Upregulation of VCAM-1 has been 
associated with immunity to pulmonary M.tb infection (Feng et al., 2000). MAdCAM-1 is 
expressed largely in the gastrointestinal (GI) tract where it binds to alpha-4-beta-7 (α4β7) and 
specifically recruits leukocytes to the intestinal mucosa (Streeter et al., 1988).  
 
1.6 Immune response to TB  
 
1.6.1 Innate immune response to TB  
The innate cells that play a major role in the primary response to TB include macrophages, 
neutrophils, DCs and NK cells.  Alveolar macrophages initiate phagocytosis through pattern 
recognition receptors (PRRs). By initiating phagocytosis, the innate effector function begins 
and other immune cells are attracted by the production of inflammatory cytokines. IL-8 
promotes the recruitment of neutrophils, thereafter NK cells and T cells produce IFN-γ upon 
stimulation with IL-12 (Sia et al., 2015). In response to M.tb, IL-12 responses have been 
shown to play an important role since individuals who do not produce this cytokine were 
shown to be more susceptible to the infection (Casanova and Abel, 2002).  
 
In sputum and bronchoalveolar lavage (BAL) of active TB patients, neutrophils are a major 
subclass of the innate immune cells and arrive within hours of infection. Neutrophils are able 
to produce and secrete a number of antimicrobial enzymes during infection, thus restricting 
growth in the infected macrophage (Eum et al., 2010, Sia et al., 2015). Apoptosis of infected 
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macrophages is promoted by neutrophil action, limiting the existence of M.tb in the infected 
host cells (Tan et al., 2006, Sia et al., 2015).  
 
During mycobacterial infection, DCs are important for establishing an adaptive immune 
response. In response to M.tb, DCs are considered one of the main cells in presenting 
antigens to T cells. Upon stimulation, DCs are able to produce inflammatory cytokines which 
direct  T cell response (TNF and IFN-γ) (Flynn and Chan, 2001) and  recruit cells to the site 
of infection  (IL-1 and IL-6) (Giacomini et al., 2001). Previous studies have found that DCs 
have the ability to strengthen the cellular immune response against M.tb infection (Henderson 
et al., 1997, Förtsch et al., 2000, Tascon et al., 2000). DCs are highly represented at sites of 
M.tb infection at the onset of inflammatory responses (Sertl et al., 1986, Van Haarst et al., 
1994). Immature DCs are present in the mucosa of the lung and are highly specialized for 
antigen uptake as well as processing. Maturation occurs after DCs interact with M.tb. 
Thereafter DCs migrate to lymphoid organs, where they prime T cells through cell surface 
expression of MHC and costimulatory molecules and through the secretion of 
immunoregulatory cytokines such as: IL-12 (Banchereau and Steinman, 1998). 
 
NK cells are granular lymphocytes characterized by a strong cytolytic capacity. NK cells 
were found to limit the replication of M.tb by producing specific soluble mediators (GM-
CSF, IL-12, TNF-𝛼, IL-22, and IFN-𝛾) (Zhang et al., 2006). Granulysin and perforin are 
derived antimicrobial factors of NK cells, and are able to indirectly limit the progression of 
M.tb through the lysis of infected host cells (Sia et al., 2015).  
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1.6.2 Adaptive immune response to TB  
The protective response against M.tb is dependent on the dominant role of CD4+ T cells 
(Kaufmann et al., 2005).  Once CD4+ T cells are activated, cytokines such as IFN-γ, IL-2 and 
TNF are secreted resulting in the activation of macrophages (Flynn and Chan, 2001). The 
importance of CD4+ T cells in control of M.tb infection in humans is revealed by the steady 
increase in the risk of active TB in HIV infected individuals who have low CD4+ T cell 
counts (Selwyn et al., 1989). Additionally, CD4+ T cells are essential in increasing APC 
function through the interaction of CD40-CD40L between CD4+ T cells and the APC.  
 
Although the principle mechanisms of CD8+ T cell stimulation is not completely understood, 
it is known that CD8+ T cells add to a protective immunity against TB (Kaufmann, 2006, 
Cooper, 2009). Mycobacterial peptides presented by MHC I are needed for the stimulation of 
CD8+ T cells. The presentation usually takes place in the cytosol which is not freely accessed 
by M.tb. Therefore, two pathways have been suggested: (i) M.tb enters the cytosol of the 
infected DCs which results in direct loading of the MHC class I molecules or (van der Wel et 
al., 2007) (ii) apoptosis of M.tb infected macrophages which releases the vesicle containing 
the mycobacterial antigen,  leading to cross priming (Winau et al., 2006). CD8+ T cells 
which are specific to mycobacterial antigens are able to produce IFN-γ and secrete cytolytic 
proteins (perforin and granulysin), thereby lysing the host cells and directly attacking M.tb  
(Stenger et al., 1997). 
 
Cytokines produced in response to M.tb infection are not always favorable to host protection 
and in turn have the ability to favor M.tb replication and persistence. A number of studies 
41 
 
both in humans and animals have found that cytokines play a significant role in defining the 
outcome of M.tb infection. Transforming growth factor β (TGF-β), an anti-inflammatory 
cytokine, has the ability to counteract the protective immunity against TB by inhibiting IFN-γ 
production and T cell proliferation, resulting in the suppression of the adaptive immune 
response (Toossi et al., 1995). It has been previously shown that soluble adhesion molecules 
such as: sICAM and sVCAM correlate with TB disease severity (Mukae et al., 2003). A 
study conducted by Shi et al found increased levels of sICAM-1 in milliary and advanced TB 
disease whereas, a study by Lai et al found that sICAM-1 levels where increased in 
individuals who had active TB compared to controls (SHI et al., 1993, Lai et al., 1993). 
Mukae et al found significantly higher sICAM-1 in individuals with active TB and found it to 
be the most sensitive biomarker of TB severity (Mukae et al., 2003). Additionally, Feng et al 
showed in mice that the upregulation of sVCAM-1 was associated with immunity to 
pulmonary M.tb  (Feng et al., 1999). 
 
1.7. Immune response to HIV 
 
1.7.1. HIV transmission and mucosal immune responses  
Transmission of HIV can occur through various routes such as: sexual transmission (vaginal, 
anal or oral), perinatal transmission (child birth) and percutaneous transmission (needle 
stick). At least 80% of all HIV infections occur through sexual contact via the mucosal 
surface and the other 20% occur mainly through percutaneous methods (Cohen et al., 2011, 
Sharp and Hahn, 2011). While significantly reduced a small proportion of HIV transmission 
still occurs through mother to child transmission (MTCT) during birth and through 
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breastfeeding, especially in the resource limited settings. Majority of the individuals who are 
infected, acquire the virus via sexual contact through mucosal tissue (genital and rectal) and 
between these tissues the probability of transmission varies. During vaginal intercourse the 
probability of transmission ranges from 1/200 to 1/2000 whereas in anal intercourse the 
probability of transmission ranges from 1/20 to 1/300 (Kaul et al., 2015).  
 
Prolonged/chronic inflammation impairs mucosal barriers, permits HIV to enter target cells in 
order to establish infection (Carias et al., 2013, Nazli et al., 2010). Inflammation of the 
genital tract can be caused by sexually transmitted infections (STIs), bacterial vaginosis (BV) 
and genital micro-abrasions, which lead to an upregulation of soluble immune proteins and 
activation of susceptible cells in the vaginal mucosa (Fichorova et al., 2001, Guimarães et al., 
1997).  
 
1.7.2 HIV disease progression 
HIV disease progression is marked by a destruction of  CD4+ T cells compromising the host 
immune response (Okoye and Picker, 2013). There are varied rates at which HIV progresses 
to AIDS. These are classified as: (i) Elite controllers, living with HIV and able to maintain 
suppressed viral loads without ART (ii) Rapid progressors, which advance to AIDS within 3 
years following infection, (iii) Intermediate, which assumes a time of  3-10 years since 
infection and (iv) Long term, where CD4 count is preserved for a great length of time without 
ART therapy (Ganesan et al., 2010, Zeller et al., 1996). CD4+ T cell counts, viral load (VL) 
and immune activation are classified as predictors of disease progression (Goujard et al., 
2006). One of the main causes of a gradual loss of CD4+ T cells is immune activation, 
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regardless of VL (Deeks et al., 2004). Mucosal integrity is sustained by CD4+ T cells, and 
Th17 cells in particular, and their destruction causes damage to mucosal barriers and systemic 
translocation of microbes  (Brenchley et al., 2006b, Mogensen et al., 2010). The translocation 
of bacterial products (‘microbial translocation’) results in the production of high amounts of 
inflammatory cytokines. These include TNF, IFN-α, IFN-β and IL-1β which contribute to 
immune activation in chronically infected  individuals (Sandler et al., 2011, Miyake, 2006).  
 
High level of viral replication in the gut associated lymphoid tissue (GALT) is the defining 
feature of acute HIV infection. Early studies conducted on rhesus macaques and simian 
immunodeficiency virus (SIV) models established that a profound depletion of gut CD4+ T 
cells was accompanied by increased viral replication in the GALT (Heise et al., 1994, Veazey 
et al., 1998). In human studies, it was shown that a similar depletion of CD4+ T cells was 
observed in the initial stages of HIV infection (Guadalupe et al., 2003, Mehandru and 
Dandekar, 2008, Mehandru et al., 2004). The rapid loss of CD4+ T cells results in damage to 
the physical integrity of the gut, which has been linked to chronic systemic immune 
activation (Brenchley and Douek, 2008a, Brenchley and Douek, 2008b). Therefore, there is 
substantial evidence to propose that the events which occur in the tissues of the gut during the 
initial infection play a significant role in the pathogenesis of AIDS (Breed et al., 2015).  
 
1.7.3 Systemic immune activation 
During HIV infection the cytokines produced contribute directly to chronic immune 
activation, which begins during acute HIV infection. This in turn has an effect on 
lymphocytes in circulation and in the tissues. Previous studies have shown that HIV 
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replication in the GALT causes drastic CD4+ T cell depletion in HIV/SIV infection (Février 
et al., 2011, Veazey et al., 1998). The depletion is likely due to the infected CD4+ T cells 
being directly killed, however this is exacerbated by pro-inflammatory cytokine (IFN-α and 
TNF-α) production, which induce activation and death of uninfected CD4+ T cells (Groux et 
al., 1992). In addition, the depletion of Th17 cells results in the structural damage of the 
GALT tissues as well as the translocation of microbial products from the gut into systemic 
circulation (Brenchley et al., 2008, Brenchley et al., 2006b, Marchetti et al., 2011, Kamat et 
al., 2010, Moir et al., 2011).  
 
In pathogenic SIV/HIV infections, the translocation of microbial products from the GI tract 
and the associated systemic inflammation have been suggested to be a major driver of chronic 
immune activation (Marchetti et al., 2011, Zevin et al., 2016). A major marker of microbial 
translocation is lipopolysaccharide (LPS) which is a component of the gram-negative 
bacterial cell wall and a recognized agonist of toll-like receptor (TLR) 4 (Beutler, 2000, 
Caradonna et al., 2000, Cooke et al., 2001). It was originally proposed by Brenchley et al that 
microbial translocation is a key mechanism of mucosal immune dysfunction, chronic 
systemic immune activation and HIV disease progression (Brenchley et al., 2006a). A 
subsequent study by Brenchley et al showed significant increases of LPS levels in HIV 
infected individuals and SIV infected rhesus macaques, which correlated positively with 
innate and adaptive immune activation measures (Brenchley et al., 2006b). Since Brenchley 
et al initial finding, a number of studies have found an association between HIV infection and 
a substantial loss of CD4+ T cells in the gut, thereby resulting in microbial translocation ( 
Hunt et al., 2014, Marchetti et al., 2008). 
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1.8. Immune responses in HIV/TB infection  
 
1.8.1 Immune complexities of HIV and TB co-infection 
The progressive reduction of absolute CD4+ T cell numbers is the most obvious defect 
caused by HIV that strongly correlates with an increased risk of TB (Sonnenberg et al., 
2005). Due to the increase in TB risk just after HIV acquisition, there has been a growing 
interest in establishing if early HIV infection eliminates M.tb specific CD4+ T cells and 
whether it impairs their functional potential (Sonnenberg et al., 2005, Lawn et al., 2005b). 
 
A number of cross sectional studies have shown that in individuals who have latent TB, the 
frequency of M.tb  specific CD4+ T cells is decreased by HIV-1 in the periphery and at the 
site of disease (Jambo et al., 2014, Serbina et al., 2001, Rangaka et al., 2007). A study 
conducted by Geldmacher et al looked at a small group of participants and after 
seroconversion found that  majority of the participants had a fast decline in the rate of ESAT-
6/CFP-10 and PPD specific CD4+ T cells, attaining an undetectable level a year after 
infection (Geldmacher et al., 2008).  Additional studies have shown that in HIV-1 co-infected 
individuals with CD4 counts < 200 cells/mm3, there was an increased frequency of ESAT-
6/CFP-10 specific CD4+ T cells in active and latent TB (Hammond et al., 2008, Rangaka et 
al., 2007). From a mechanistic point of view, the susceptibility of M.tb specific CD4+ T cells 
to HIV-1 has been associated with a poor secretion of macrophage inflammatory protein 1β 
(MIP-1β). MIP-1β is a ligand of CCR5 and acts as an antagonist for HIV entry (Geldmacher 
et al., 2010). Active TB is linked with elevated expression of CCR5 on CD4+ T cells, making 
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M.tb specific cells better targets for HIV-1 (Juffermans et al., 2001, Rosas-Taraco et al., 
2006). Co-infection of M.tb and HIV-1 generally provides a microenvironment that has the 
ability to assist in the replication of HIV-1 and M.tb specific CD4+ T cell depletion. The 
remaining M.tb specific CD4+ T cells are not able to contain M.tb in co-infected individuals, 
suggesting that the functional properties of the remaining M.tb specific CD4+ T cells are 
impaired by HIV-1.  
 
A number of studies have looked at the qualitative profile of M.tb specific CD4+ cells in the 
context of HIV-1 co-infection (Canaday et al., 2015, Pollock et al., 2016). A reduction in the 
polyfunctional potential of PPD and BCG specific Th1 CD4+ T cells in both the periphery 
and BAL has been associated with individuals who are HIV-1 infected and have latent TB; 
thereby skewing the cell functional profile toward a monofunctional TNF-α response 
(Kalsdorf et al., 2009). Moreover, the proportion of CFP-10 specific CD4+ T cells that 
produce IL-2 is indirectly related to HIV-1 viremia in individuals who are HIV-1 infected and 
have latent TB. This limits the expansion of  M.tb specific T cell upon antigen recall (Day et 
al., 2008).  
 
A systemic and chronic state of immune activation induced by HIV infection affects the 
innate and adaptive immune systems (Moir et al., 2011). T cell phenotype is altered by HIV-1 
related chronic immune activation, resulting in increased expression of activation markers 
and a shift in the memory profile of T cells toward the effector phenotype and increased 
expression of exhaustion markers on effector memory subsets (Liu et al., 1997, Papagno et 
al., 2004). In individuals who are co-infected with HIV-1 and latent TB, the expression of 
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HLA-DR in  M.tb specific CD4+ T cells is significantly increased compared to individuals 
who are HIV-1 uninfected (Wilkinson et al., 2016). In BCG vaccinated infants, there was an 
association between the frequency of circulating activated HLA-DR+ CD4+ T cells and 
elevated risk of active TB (Fletcher et al., 2016). Therefore, it is plausible that HIV-induced 
T cell activation plays a role in increasing the risk of TB in HIV-1 infected individuals. 
Additionally, individuals who had latent TB expressed <10% of programmed cell death 
protein 1 (PD-1) on PPD specific CD4+ T cells irrespective of HIV-1 infection (Pollock et 
al., 2016). Conversely the expression of PD-1 on M.tb specific CD4+ T cells was 
significantly elevated in HIV-1 co-infected individuals compared to HIV-1 uninfected 
individuals (Pollock et al., 2016). The proliferation potential of PPD specific CD4+ T cells 
was marginally improved by blocking of PD-1/ programmed death-ligand 1 (PD-L1) 
pathways (Shen et al., 2016), therefore suggesting that in HIV-1 co-infected individuals the 
overexpression of PD-1 encourages T cell exhaustion and contributes to a suboptimal  M.tb 
response. 
 
Furthermore, HIV-1 infection disrupts the balance in  M.tb specific Th subsets, thus 
suggesting that  M.tb specific responses are shifted toward a more pathogenic or 
inflammatory profile due to HIV-1 (Riou et al., 2016). A study conducted by Bell et al 
looked at the Th responses in a small number of M.tb/HIV co-infected individuals by 
measuring transcriptional profiles of punch biopsies taken at the site of mycobacterial 
challenge (Bell et al., 2016). Individuals, who were co-infected with a positive TST and a 
stable CD4 count, displayed conserved Th responses and poor IL-10 inducible responses, 
thus proposing that impairment of regulatory pathways could be harmful for M.tb control. 
This supports the idea that a stable immune response is vital for M.tb containment. In 
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comparison, individuals who were TB/HIV co-infected with clinically anergic TSTs showed 
a significant decrease in circulating CD4 counts. Additionally, the TST transcriptome of these 
individuals showed immunological anergy with a decrease in cellular recruitment, cytokine 
activity as well as in the innate immune responses (Bell et al., 2016).  
 
Animal studies have shown that CD8+ T cells specific to M.tb play a protective role in 
controlling M.tb infection during latency (Woodworth and Behar, 2006). A study conducted 
on macaques found that protection from TB reactivation was related to an increase in 
memory CD8+ T cell proliferation and high granzyme B production in the lung (Foreman et 
al., 2016). Not many studies have looked at the impact of HIV-1 infection on M.tb specific 
CD8+ T response. However, a study conducted by Kalokhe et al in individuals with LTBI 
found that CD8+ T cells from individuals who are HIV-1 co-infected showed a decrease in 
the expression of CD107a and this likely suggests that HIV co-infection compromises the 
function of CD8+ T cells in LTBI (Kalokhe et al., 2014). It is well established that the 
hallmark of HIV-1 mediated chronic activation has the ability to severely affect the CD8 
compartment (Breton et al., 2013). It is also possible that premature exhaustion of M.tb 
specific CD8+ T cells is promoted by HIV, which affects their functional capacity and 
potential to survive. Therefore, more studies need to be conducted in order to fully describe 
the effect of HIV-1 on M.tb specific CD8+ responses. 
 
The immunological environment during M.tb infection is distinguished by irregularities in the 
production of cytokines and chemokines which are believed to (i) increase T cell activation, 
(ii) increase HIV replication and (iii) result in a dysfunctional immune response (Toossi et 
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al., 2001a, Goletti et al., 1996, Toossi et al., 2001b, Hertoghe et al., 2000, Vanham et al., 
1996). The effect of cytokines and chemokines in TB/HIV infected individuals remains 
largely unexplored. There have been contradictory studies on the effect of TB treatment on 
VL and plasma cytokine response. Elevated pro-inflammatory immune response and a 
reduced VL in response to TB therapy were observed in some studies (Goletti et al., 1996, 
Toossi et al., 2001b, Hertoghe et al., 2000, Vanham et al., 1996, Dean et al., 2002), whereas 
other studies have not seen this difference (Kalou et al., 2005, Morris et al., 2003, Lawn et 
al., 1999). A study conducted by Mihret et al looked at the difference in the immune response 
before and after TB treatment in TB/HIV co-infected individuals compared to individuals 
who had TB and were HIV uninfected. The study found that there  were statistical differences 
in the plasma levels of IFN-γ, IL-4, monocyte chemotactic protein-3 (MCP-3), MIP-1β and 
interferon gamma-induced protein 10 (IP-10) prior to and after TB treatment in HIV 
uninfected participants (Mihret et al., 2014). 
 
Previous studies conducted on TB/HIV co-infected individuals in KZN have shown 
differences in host responses to TB. A study conducted by Thobakgale et al found an 
association between the production of interleukin 1-beta (IL-1β) by innate cells (monocytes 
and myloid dendritic cells) following BCG and TLR 2,4,7/8 stimulation with differences in 
TB recurrence outcomes. They found that the production of IL-1β in response to BCG 
stimulation was associated with increased TB risk in a SA population (Thobakgale et al., 
2017). Sivro et al measured cytokines in plasma samples from the TB Recurrence upon 
Treatment with HAART (TRuTH) cohort in SA and found that inflammatory cytokines such 
as: IL-1β, IL-6 and interleukin-1 receptor antagonist (IL1-Ra) where associated with 
increased risk of TB reactivation (Sivro et al., 2017) thus indicating that systemic 
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inflammation plays a role in TB disease. These studies provide evidence that the 
inflammatory cytokines have an impact on reactivation of TB and could be used as 
biomarkers for effective TB management. 
 
1.8.2 Gut-Lung axis  
The human microbiota is composed of microbial communities which reside at different sites 
such as the: gut, airways, vagina, skin and mouth (Cho and Blaser, 2012). Dysbiosis of the 
gut microbiota has been associated with respiratory infections and lung disorders (Trompette 
et al., 2014, Shukla et al., 2017). Studies previously conducted on mice have shown that due 
to antibiotic intake, certain species (such as Clostridium species) within the gut microbiota 
get depleted and this was shown to influence allergic inflammation and lung diseases (Russell 
et al., 2013, Dharmage et al., 2015, Metsälä et al., 2015). Chronic gut diseases such as: 
inflammatory bowel disease (IBD) and irritable bowel disease (IBS) were shown to impact 
lung health (Roussos et al., 2003, Rutten et al., 2014). Pulmonary involvement such as: 
inflammation and impaired lung function is found in up to 50% of adults with IBD and 33% 
of patients with IBS (Yazar et al., 2001, Keely et al., 2012). Additionally, mouse studies have 
previously shown that after the administration of neomycin to remove sensitive gut bacteria, 
the lungs become increasingly susceptible to the influenza virus infection (Ichinohe et al., 
2011, Looft and Allen, 2012).  
 
Opposite effect has been shown as well, where changes in the lung microbial community can 
influence the gut microbiota composition. In mice models, influenza infection in the 
respiratory tract increased the amount of Enterobacteriaceae and led to a reduction in 
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Lactobacilli and Lactococci species in the microbiota of the intestines (Looft and Allen, 
2012). Sze et al showed in mice that the dysbiosis in the microbiota of the lungs after LPS 
administration was accompanied by the disturbance in their gut microbiota, which is due to 
bacteria moving from the lung and into the bloodstream (Sze et al., 2014). Another important 
and currently unexplored research area is the impact of long-term TB treatment on bacterial 
communities of the vaginal tract and how these changes could be impacting HIV 
susceptibility.  
 
Overall these findings indicate an inflammatory “cross talk” between different mucosal 
tissues. HIV-mediated destruction of the gut mucosal tissues and the resulting microbial 
translocation could have profound impacts on TB susceptibility and disease in co-infected 
individuals.  
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Rationale  
Globally the burden of TB and HIV infections is highest in SA and often concomitant 
(Jacobson et al., 2015). Therefore, there is a dire need to improve the diagnosis and 
management of TB/HIV co-infected individuals.  
TB and HIV infections have been related to changes in a number of host protein expression 
(Sivro et al., 2017, Achkar et al., 2015). Inflammatory responses of both HIV and TB act 
similarly, whereby the initial response to infection is needed to prevent the infection 
however, if left uncontrolled it can lead to immune mediated pathology (Guo et al., 2015, 
Sandler et al., 2014, Veazey et al., 2016). Trafficking of immune cells from the periphery to 
the affected tissues plays an important role in the pathogenesis of both TB and HIV (Wilson 
and Sereti, 2013). The migration of leukocytes from circulation to tissues is a multistep 
process, which is mediated by the interaction of cell surface glycoproteins (“homing 
receptors”) with endothelial molecules expressed in a tissue-restricted manner (“vascular 
addressins”) (Butcher et al., 1999, Butcher and Picker, 1996). This study will look at three 
adhesion molecules: sICAM, sVCAM and sMAdCAM that are known to play an important 
role in cell recruitment to the mucosal tissues including lung and the GI tract as well as TGF-
β and LBP, which are known for their role in inflammation/wound healing and microbial 
translocation respectively. Although several chemokine receptors have been implicated in T 
cell trafficking to the lung during disease progression, there continues to be a lack of data 
regarding lymphocyte trafficking markers and their role in TB. Therefore given the role of 
lymphocyte trafficking in HIV, it is important to assess the role of soluble lymphocyte 
trafficking markers in TB and TB/HIV co-infection. Susceptibility to both HIV and TB 
infection as well as the course of the disease are likely to be affected by the inflammation 
induced changes in cytokine/chemokine expression.  
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Here we hypothesize that concentrations of soluble lymphocyte markers will increase during 
active TB disease and will contribute to inflammation in TB and TB/HIV co-infection.  
 
Aim  
Characterize soluble markers of lymphocyte trafficking and inflammation in the context of 
TB and TB/HIV co-infection 
 
Hypothesis  
Increased plasma expression of lymphocyte trafficking markers (ICAM, VCAM and  
MAdCAM) as well as inflammatory LBP and TGF-β will positively associate with onset of 
TB disease and can be used to predict TB recurrence.  
 
Specific objectives  
1. To evaluate  the role of ICAM, VCAM, MAdCAM, TGF-β and LBP plasma 
expression as predictors of TB recurrence (TRuTH ) by standard and multiplex 
ELISAs 
2. To evaluate  the effect of active TB disease and TB treatment completion (IMPRESS) 
on the plasma expression of soluble ICAM, VCAM, MAdCAM, TGF-β and LBP by 
standard and multiplex ELISAs 
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CHAPTER 2. Materials and Methods 
 
2.1. Ethics 
Informed written consent was obtained from all study participants prior to enrolment. The 
University of KwaZulu-Natal’s Biomedical Research Ethics Committee (BE659/17) 
approved this study. Ethical approval received covered the use of stored samples in this 
study. 
 
2.2. Study participants 
The presented study was performed on stored plasma specimens from the CAPRISA 005 
TRuTH and the CAPRISA 011 Improving Retreatment Success (IMPRESS) cohorts. Patients 
in both studies were recruited and treated at an urban clinic (CAPRISA eThekwini Research 
Clinic) in KZN, South Africa.   
 
2.2.1. TRuTH cohort 
TRuTH was a cohort observational study that investigated the rate of TB recurrence in adults 
who completed therapy for pulmonary TB and were on highly active antiretroviral therapy 
(HAART) (Clinical trial NCT 01539005). Participants from this cohort were previously 
enrolled in the CAPRISA 003 SAPiT trial, which investigated the timing of ART initiation 
during pulmonary TB treatment. Participants that entered TRuTH had a confirmatory 
negative status for TB upon completion of TB treatment. While retained on ART, participants 
were screened four times a year for a maximum of 4 years for recurrence of TB.  
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A nested case: control study was conducted for TRuTH samples, where cases were defined 
by the recurrence of TB with the availability of a pre-recurrence sample, which was matched 
to controls who were participants that had no indication of recurrence during follow up. To 
analyse the effect of measured analytes on TB recurrence, case:control matching (1:3) was 
carried out based on the ART start date. Cases were sampled at a minimum of 3 and 
maximum of 9 months prior to TB recurrence and controls at comparable time points to 
minimize the difference in sample cryopreservation length between groups. A subset of cases 
was followed longitudinally at additional time points: Recurrence/TB (2-month window 
before or after TB recurrence) and Cure/Post TB (capturing a 2 month-window before and 3 
month- window after recurrent TB treatment completion date).  
 
 
Figure 3. Pictorial timeline illustrating sample collection in TRuTH 
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2.2.2. IMPRESS cohort 
IMPRESS was an open labelled phase 1 and 2 randomized control study (Clinical trials NCT 
02114684), which compared previously treated TB patients with two regimens for treatment 
of smear positive pulmonary TB. The first was a 24 week regimen consisting of 
Moxifloxacin, INH, RMP and PZA taken orally and the second was a standard drug regimen 
(INH, RMP, PZA and EMB). Patients were stratified by HIV status and randomized into the 
intervention and control arm, where TB therapy was administered for 6 months. Participants 
included in this study had to be >18 years of age, have had a documented history of 
confirmed TB in the last 3 years and have had a positive sputum smear of M.tb. This study 
consisted of men and women who were HIV infected and uninfected.  
To analyse the effect of active disease and TB treatment completion on the expression of the 
here measured analytes (MAdCAM, ICAM, VCAM, LBP, TGF-β1, TGF-β2 and TGF-β3), a 
subset of HIV infected and HIV uninfected men and women were sampled at two time-
points: active disease and post TB treatment completion. No matching was performed.  
 
2.3. Collection and Processing of Samples 
Acid citrate dextrose (ACD) and Ethylenediaminetetraacetic acid (EDTA) tubes were used to 
collect peripheral blood. The blood was centrifuged for 7 minutes at 1400rpm, the plasma 
was retrieved and cryopreserved for future analysis at -80ºC.  
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2.3.1. Chest Radiograph 
Participants underwent a digital chest x-ray every 6 months at the Prince Cyril Zulu 
Communicable Disease Centre (PCZCDC). 
 
2.3.2. HIV testing 
Uni-Gold (Trinity Biotech, Ireland) and Alere Determine (Alere Scarborough, Inc) rapid HIV 
tests where used to test the samples for HIV.  Results positive for HIV were confirmed by a 
second licenced rapid HIV test and the discordant results were confirmed by an Enzyme-
Linked Immunosorbent Assay (ELISA). 
 
2.3.3. Analysis of CD4 count 
All participants who were HIV positive had their CD4 counts measured by collecting whole 
blood in EDTA tubes and analysed with the TruCOUNT method (BD Biosciences, San Jose, 
US). 
 
2.3.4. Analysis of viral load 
A nested PCR with Expand Long Template PCR system (Roche Diagnostics) was used to 
determine viral loads in HIV positive samples. The assay yields a lower detection limit of 40 
HIV RNA copies/ml with a range of 40-107 HIV RNA copies/ml. 
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2.4. Multiplex Assays 
 
2.4.1. Millipore Milliplex MAP Human Sepsis assay 
The Milliplex MAP Human Sepsis kits were used to simultaneously quantify ICAM and 
VCAM, by using small volumes of plasma. Prior to the start of the assay, all reagents were 
brought to room temperature (RT). The reagents where prepared as per manufacturer’s 
instructions, with minor changes. A fourfold dilution series was made for the standard 
(Figure 3). The serum matrix, once reconstituted with deionized water (dH2O) was further 
diluted in sample diluent. The patient plasma samples (5 µl) were diluted in 195 µl of serum 
matrix to get a final 1:40 dilution. 
 
Figure 4. Illustration of the fourfold Milliplex MAP Human Sepsis standard serial dilution 3  
3Adapted from the Millipore Milliplex instruction manual 
Plates were pre-wet with 200 µl/well of assay buffer and incubated on a shaker for 10 
minutes at RT. Following the removal of assay buffer, 25 µl of standards and controls was 
added to the respective wells and 25 µl of assay buffer was added to all the sample wells. 
Matrix solution (25 µl/well) was added to the wells containing the background, standards and 
controls. Diluted samples (25 µl) were added to the appropriate wells and 25 µl of magnetic 
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beads were added to each well in the plate. The plate was then sealed, covered with foil and 
incubated on a shaker at 250 ± 50 rpm overnight at 4ºC. 
 
The plate was washed twice with 100 µl wash buffer on the Bio-Plex Wash Station. 25 µl of 
detection antibodies/well were added to the plate and incubated for 1 hour at RT. After 
incubation, 25 µl of Streptavidin-Phycoerythrin was added and the plate was incubated for 30 
minutes at RT. The plate was then washed three times with 100 µl of wash buffer and 100 µl 
of sheath fluid was added to each well. The beads were re-suspended on a shaker for 5 
minutes at 250 ± 50 rpm. The plate was analysed on the Bio-Plex™ 200 plate reader. 
 
Commercial Kits used: 
Customized Milliplex MAP Human Sepsis Mag Bead Panel 1 (ICAM and VCAM) (Cat# 
HSP1MAG-63K-02) 
 
Equipment Used: 
Bio-Plex Pro™ II Wash Station 
Bio-Plex™ 200 System 
Stuart Orbital Shaker 
Vortex 
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2.4.2. Transforming growth factor – beta (TGF-β) assay 
The Transforming growth factor-beta (TGF-β) kit (Bio-Rad, USA) was used to determine the 
plasma levels of TGF-β1, TGF-β2 and TGF-β3. Prior to the start of the assay, all reagents, 
samples and controls were brought to RT and were prepared as per the manufacturer’s 
instructions. A fourfold serial dilution was made of the standard (Figure 4).  
 
 Figure 5. Illustration of the fourfold TGF-β standard serial dilution4 
4Adapted from the Bio-Plex Pro instruction manual 
 
Once thawed, the samples were activated by adding 2.5 µl of 1 N hydrochloric acid (HCl) to 
12.5 µl of sample. The samples were then vortexed and incubated at RT for 10 minutes. 
Thereafter, the samples were neutralized by adding 2.5 µl of 1.2 N Sodium hydroxide 
(NaOH)/ 0.5 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). To make 100 
ml of 1.2 N NaOH/ 0.5 M HEPES, 20 g of NaOH was added to 20 ml of  dH2O and topped 
up to 50 ml with dH2O to make 10 N NaOH . Thereafter, 12 ml of 10N NaOH was added to 
75 ml of dH2O. Once mixed well, 11.9 g of HEPES was added and the volume was adjusted 
to 100 ml with dH2O.  
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To run the assay, the magnetic beads were vortexed and added (50 µl/well) to the plate. The 
plate was washed twice (100 µl) on the Bio-Plex wash station. The diluted standards, 
samples, controls and blanks were vortexed for 5 seconds and 50 µl was added to the 
respective wells. The plate was covered with sealing tape and incubated on a shaker at 250 ± 
50 rpm at RT for 2 hours. The plate was washed three times with 100 µl of wash buffer. 
Detection antibodies were vortexed and 25 µl was added to each well of the plate. The plate 
was covered with aluminium foil and incubated at room temperature for 1 hour on a shaker at 
250 ± 50 rpm. The plate was washed three times with 100 µl of wash buffer and 50 µl per 
well of SA-PE was added to the plate. The plate was covered with aluminium foil and 
incubated on a shaker at 250 ± 50 rpm for 30 minutes at RT. The plate was then washed three 
times, and the beads were re-suspended with 125 µl of assay buffer. The plate was analysed 
on the Bio-Plex ™ 200 system.  
 
Commercial Kits and reagents used: 
1N Hydrochloric Acid (Cat# KC-HCL-1N) 
NaOH pellets (Cat# S8045-500G) 
HEPES Free Acid Ultrol Grade (Cat#391338-100GM) 
Bio-Plex Pro TGF-β Panel (Cat#171W4001M)  
 
Equipment used: 
Bio-Plex Pro™ II Wash Station 
Bio-Plex™ 200 System 
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Stuart Orbital Shaker 
Vortex 
 
2.5. Standard Sandwich ELISA Assays 
 
2.5.1. Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM-1) assay 
The Hycult Biotech HK337 Human sMAdCAM-1 ELISA Kits (Hycult, USA) were used to 
determine the level of sMAdCAM-1 in plasma samples. Prior to the start of the assay, all the 
reagents were brought to RT. The reagents were prepared as per manufacturer’s instructions. 
A serial dilution was made for the standards (Figure 5). The samples (20 µl) where diluted in 
180 µl of dilution buffer for a final 1:10 dilution. 
 
 
Figure 6. Illustration of the sMAdCAM-1 standard serial dilution5 
5Adapted from the Hycult Biotech HK337 instruction manual 
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In a pre-coated plate 100 µl of standards, samples and controls were added to their respective 
wells and incubated on a plate shaker for 1 hour at 250± rpm. The plate was washed manually 
three times with 200 µl of wash buffer. The plate was then coated with 100 µl of diluted 
tracer and incubated for 1 hour at RT. After incubation, the wash step was repeated and 
thereafter diluted streptavidin-peroxidase substrate (100 µl/well) was added and the plate was 
incubated for 1 hour at RT. The wash step was repeated and 100 µl of TMB substrate was 
added to each well of the plate and incubated for 30 minutes at RT. The reaction was stopped 
by adding stop solution (2% oxalic acid) (100 µl /well) to the plate. The plate was analysed at 
450nm on the ELISA plate reader. 
 
Commercial Kits used: 
Human sMAdCAM-1 ELISA kit (Cat#HK337-02) 
 
Equipment used: 
Versamax ELISA Plate Reader 
Stuart Orbital Plate Shaker 
Vortex 
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2.5.2. Human Lipopolysaccharide – Binding Protein (LBP) Assay 
The Human Lipopolysaccharide-Binding Protein (LBP) kit (R&D systems, USA) was used to 
measure the human LBP plasma levels. Prior to the start of the assay, all reagents were 
brought to RT. A two fold serial dilution of the standard was made (Figure 6). Capture 
antibody was diluted in phosphate buffer saline (PBS) without a carrier protein. The plate 
was coated with the diluted capture antibody; it was then sealed and incubated overnight at 
RT. On the following day, the plate was manually washed three times with wash buffer (200 
µl/well). The plate was blocked with 300 µl of reagent diluent and incubated for 1 hour at 
RT. Wash step was repeated after incubation. 
 
 
 
 
 
Figure 7. Illustration of the twofold LBP standard serial dilution6 
6Adapted from the DuoSet ELISA instruction manual 
 
To a pre-coated plate 100 µl of sample and standards were added to their respective wells; the 
plate was then covered and incubated at RT for 2 hours. The plate was manually washed 
three times with wash buffer (200 µl/ well). Streptavidin-HRP (100 µl/well) was added to the 
plate, covered with foil and incubated at RT for 20 minutes. The wash step was repeated and 
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substrate solution (100 µl/well) was added to the plate and then incubated at RT for 20 
minutes. Stop solution (2N H2SO4) (50 µl/well) was added to the plate. The plate was read 
immediately at 450nm with a wavelength correction of 540nm on an ELISA microplate 
reader.  
 
Commercial Kits and Reagents Used: 
Human LBP DuoSet, 5 Plate (Cat# DY870-05) 
DuoSet Ancillary Reagent Kit 2, 5 Plate (Cat# DY008)  
 
Equipment used: 
Versamax ELISA Plate Reader 
Stuart Orbital Shaker 
Vortex 
 
2.6. Statistical analysis 
 
All specimens were analyzed, blinded to the clinical status, with longitudinal samples 
analyzed on the same plate. GraphPad Prism version 7.05 (GraphPad software, La Jolla, CA) 
and SPSS version 24 were used to perform the statistical analysis.   
For comparison of baseline characteristics of TRuTH samples, the Wilcoxon signed ranks 
and the McNemar tests were used. TRuTH data were modeled using a univariate and 
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multivariable conditional logistic regression to account for matching. Data was square root 
transformed in order to achieve normality in distribution. Square root transformation was 
chosen due to the slightly right-skewed structure of the original dataset. TB recurrence status 
was used as a dependent variable with each analyte modeled independently as an independent 
variable. Multivariable analysis adjusted for a number of potential confounders including: 
age, body mass index (BMI), CD4 count, VL, presence of lung cavities, previous history of 
TB, and WHO disease stage (4 vs 3). Longitudinal analysis was performed by a paired t-test.  
 
For comparison of baseline characteristics in IMPRESS, the Mann-Whitney and the Fishers 
exact tests were used. D’Agostino-Pearson omnibus normality test was used to determine 
normality, if the data was normally distributed a paired t-test was conducted and a Wilcoxon 
signed-rank test was conducted for non-normally distributed data. Individuals that failed 
treatment were excluded from the analysis.  
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CHAPTER 3. Results 
 
3.1. Study Participants Characteristics and Demographics  
 
3.1.1. TRuTH cohort 
The final analysis included 139 participants, of which 37 were cases and 102 were controls. 
For cases there were 18 males and 19 females and for controls there were 45 males and 57 
females. During sample collection the median age was 36 [interquartile range (IQR) 33-41] 
years for cases and 39 (IQR 33-46) years for controls (p=0.0179). The median CD4 count for 
cases was 479 cell/mm3 (IQR 339-834) and for controls 458.5 cells/mm3 (IQR 358.8 – 635.3) 
(p=0.596). Despite ART some participants had delectable viral loads: the mean VL for cases 
was 1.61 log copies/ml and 1.52 log copies/ml for controls (p=0.376). A detailed list of the 
cohort characteristics can be seen in Table 1. 
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Table 1. Cohort characteristics of study participants from TRuTH 
 
Variables Recurrence of TB 
(N = 37) 
No Recurrence of TB  
(N = 102) 
p-value 
SAPiT enrollment    
Randomization arm, n 
(%) 
   
Early Arm 12 (32.4) 11 (10.8) - 
Post-Intensive Phase 15 (40.5) 39 (38.2)  
Post-Continuation Phase 10 (27) 52 (51)  
Age (y), [median(IQR)] 32 (27 - 37) 34 (28 - 40) 0.037 
Body mass index (kg/m2) 21.51 (19.57 - 23.20) 21.84 (19.86 - 25.70) 0.055 
CD4 count (cells/mm3), 
median (IQR) 
146 (72.25 - 236) 144.5 (81 - 256) 0.682 
Viral load (log 
copies/mL), mean (SD) 
5.05 (0.80) 5.15 (0.76) 0.36 
Gender, n (%)   - 
Male 18 (48.6) 45 (44.1)  
Female 19 (51.4) 57 (55.9)  
WHO Stage, n (%)   0.763 
3 35 (94.6) 95 (93.1)  
4 2 (5.4) 7 (6.9)  
Previous TB, n (%)   0.3545 
Yes 13 (35.1) 32 (31.4)  
No 24 (64.9) 70 (68.6)  
Lung cavities, n (%)   0.245 
No 19 (51.4) 53 (52.0)  
One 9 (24.3) 33 (32.4)  
Both 5 (13.5) 5 (4.9)  
SAPiT ART Initiation    
CD4 count (cells/mm3), 
median (IQR) 
144 (90.50 - 266) 155 (93 - 259.30) 0.6793 
Viral load (log 
copies/ml), mean (SD) 
4.94 (0.82) 5.05 (0.84) 0.466 
End of TB treatment in 
SAPiT 
   
CD4 count (cells/mm3), 
median (IQR) 
223 (144 - 447) 191 (101.8 - 328.3) 0.0008 
Viral load (log 
copies/ml), mean (SD) 
2.98 (1.09) 3.96 (1.41) <0.0001 
Variables at sample 
collection 
   
Age (y), median (IQR) 36 (33 - 41) 39 (33 - 46) 0.0179 
CD4 count (cells/mm3), 
median (IQR) 
479 (339 - 834) 458.5 (358.8 - 635.3) 0.596 
Viral load (log 
copies/ml), mean (SD) 
1.61 (0.70) 1.52 (0.60) 0.376 
Abbreviation: ART, antiretroviral therapy; IQR, interquartile range; SD, standard deviation; TB, 
tuberculosis; WHO, World Health Organization 
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3.1.2. IMPRESS Cohort  
The IMPRESS study was an open labelled randomized control trial which included both HIV 
infected and HIV uninfected participants who had active TB. The original study design 
included 41 HIV infected and 37 HIV uninfected participants, however due to sample 
availability the main analysis included 41 HIV infected and 33 HIV uninfected participants. 
Of the 78 participants, there were 24 and 31 HIV infected and uninfected male and 17 and 6 
HIV infected and uninfected female participants respectively (p=0.024). The median age was 
35 (IQR 31.75-42.5) years for HIV infected participants and 33 (IQR 24-45) years for HIV 
uninfected participants (p=0.490). As expected, HIV infected participants had a higher 
number of previous TB episodes compared to HIV uninfected participants and 3 HIV 
infected participants failed TB treatment (Mahtab and Coetzee, 2017). A detailed list of the 
cohort characteristics can be seen in Table 2. 
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Table 2. Cohort characteristics of study participants from IMPRESS 
 
Variables HIV Infected (N=41) HIV Uninfected (N=37) p-value 
IMPRESS Enrolment    
Randomization arm, n (%)   1 
HRZE – Control 21 (51.2) 19 (51.4)  
HRZM – Active 20 (48.8) 18 (48.6)  
Age (y), [median (IQR)] 35 (31.5-42.5) 33 (24 – 45) 0.490 
Gender, n (%)   0.024 
Male 24 (58.5) 31 (83.8)  
Female 17 (41.5) 6 (16.2)  
Body mass index (kg/m2) 19.7 (17.75 – 22.81) 19.6 (18.28 – 21.51) 0.732 
CD4 count (cells/mm3), median 
(IQR)a 
243.5 (124.8 – 396) -  
Viral load (log copies/mL), mean 
(SD)b 
3.60 (1.75) -  
Chest Findings, n (%)c   - 
Abnormal 40 (100) 30 (100)  
Normal 0 0  
Cavities Right, n (%)d   0.237 
Yes 18 (45.0) 18 (60.0)  
No 22 (55.0) 12 (40.0)  
Cavities Left, n (%)e   0.335 
Yes 16 (40.0) 16 (53.3)  
No 24 (60.0) 14 (46.7)  
    
IMPRESS Follow Up    
Body mass index (kg/m2) 21.17 (19.45 – 24.33) 21.67 (19.74 – 22.28) 0.515 
CD4 Count, n (%)   - 
Detectable 4 (9.8) -  
Undetectable 37 (90.2) -  
Viral load, n (%)    
Detectable 16 (39) -  
Undetectable 25 (61) -  
Previous TB, n (%)f   0.703 
1 35 (85.4) 32 (86.5)  
2 4 (9.8) 3 (8.1)  
3 - 1 (2.7)  
4 - 1 (2.7)  
WHO staging, n (%)    
3 37 (90.2) 37 (100)  
4 4 (9.8) -  
Chest Findings, n (%)g   0.660 
Normal 2 (5.7) 3 (9.7)  
Abnormal 33 (94.3) 28 (90.3)  
Cavities Right, n (%)h   0.561 
Yes 7 (21.2) 8 (28.6)  
No 26 (78.8) 20 (71.4)  
Cavities Left, n (%)i   0.375 
Yes 6 (18.2) 8 (28.6)  
No 27 (81.8) 20 (71.4)  
Failed TB Treatment, n (%) 2 (4.9) 0  
Recurrent TB, n (%) 1 (2.4) 0  
Missing data:  a2, b1,c18, d8, e8, f2, g12, h17, i17 
Abbreviations: IQR, interquartile range; HRZE, Isoniazid, Rifampicin, Pyrazinamide, Ethambutol; HRZM, 
Isoniazid, Rifampicin, Pyrazinamide, Moxifloxacin; SD, standard deviation; TB, tuberculosis; WHO, World 
Health Organization. 
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3.2. Quality Control of Assays 
 
3.2.1. Detectability and inter- and intra-plate variability of measured analytes for 
TRuTH and IMPRESS  
Detection levels of the measured analytes [sMAdCAM, sICAM, sVCAM, LBP and TGF- β 
(TGF-β1, TGF-β2 and TGF-β3)] was assessed for study samples. Figures 7A and 7B depicts 
the percent (%) detectability of the measured analytes in TRuTH and IMPRESS samples 
respectively. All TRuTH samples measured for sMAdCAM, sICAM, sVCAM and LBP 
produced a value within the range of the standard curve (100% detectability, Figure 7A). 
TRuTH samples measured for TGF-β1, TGF-β2 and TGF-β3 had high levels of detectability, 
where TGF-β1 was 97.92% and TGF-β2 and TGF-β3 were 89.06% respectively (Figure 7A). 
All IMPRESS samples measured for sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3 
had values inside the range of the standard cure, whereas sMAdCAM had % detectability of 
99.34% (Figure 7B).  
 
To check for discrepancies and inaccuracies in the way the assays were performed, the intra-
plate and inter-plate % coefficient of variation (CV) for each soluble marker was calculated 
(Table 3). For sMAdCAM, sICAM, sVCAM and LBP, 7 standards were run in duplicate 
whereas for the TGF-β (TGF-β1, TGF-β2 and TGF-β3) 8 standards were run in duplicates to 
determine the intra-plate variability of the assays. It should be noted from Table 3 that the 
intra-plate variability was relatively low for all the soluble markers measured [Median CV = 
3.20 for sMAdCAM, 4.40 for sICAM, 3.91 for sVCAM, 3.50 for LBP, and 6.30 for TGF-β].  
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For the inter-plate variability analysis, 4 control plasma samples were included on all plates. 
Inter-plate variability of sMAdCAM, sICAM, sVCAM and LBP for both TRuTH and 
IMPRESS were combined since the controls used for these assays were the same. It can be 
noted that the inter-plate variability of sICAM, sVCAM, LBP and TGF-β were relatively low 
[Median Coefficient of variation (CV) 12.27 for sICAM, 11.65 for sVCAM, 11.62 for LBP 
and 17.43] indicating consistency between the plates (Table 3). sMAdCAM % CV was 
slightly higher [Median Coefficient of variation (CV) 29.80], potentially due to differences in 
the color reagent development at the final step of the assay (Table 3). To minimize the effects 
of inter-plate variability on data analysis, longitudinal samples from the same individuals 
were run on the same plate.  
 
Figure 8. Percent (%) Detectability of measured analytes [sMAdCAM, sICAM, sVCAM, 
LBP and TGF-β (TGF-β1, TGF-β2 and TGF-β3)] in A) TRuTH and B) IMPRESS plasma 
samples. 
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Table 3. Intra- and Inter-plate percent (%) coefficient of variation (CV) for plasma 
sMAdCAM, sICAM, sVCAM, LBP and TGF-β measured for TRuTH and IMPRESS 
samples. 
Soluble Marker 
Intra-plate %CV median 
(IQR) 
Inter-plate %CV median 
(IQR) 
sMAdCAM 3.20 (0.80 - 8.60) 29.80 (28.11 - 33.27) 
sICAM 4.40 (1.19 - 9.43) 12.27 (11.18 - 13.35) 
sVCAM 3.91 (2.18 - 10.56) 11.65 (9.72 - 13.58) 
LBP 3.50 (1.60 - 7.50) 11.62 (10.49 - 15.94) 
TGF-β  6.30 (0.90 – 14.63) 17.43 (10.17 – 26.69) 
 
3.3 Measured analytes as predictors of TB recurrence 
To determine if measured plasma analytes had an effect on the rate of TB recurrence, we 
conducted a univariate and multivariable conditional logistic regression analysis on the cases 
(Recurrence of TB) and controls (No recurrence of TB). In the univariate analysis, two 
cytokines were associated with increased rates of TB recurrence: sICAM (OR 1.047, 95% CI 
1.014 – 1.081, p = 0.005) and LBP (OR 3.283, 95% CI 1.018 – 10.588, p = 0.047) (Table 4, 
Figure 8). This stayed true in multivariable analysis after correcting for WHO stage of the 
disease, BMI, lung cavities, age, CD4 count, VL, gender and previous history of TB: sICAM 
(OR 1.052, 95% CI 1.012 – 1.095, p = 0.011) and LBP (OR 5.133, 95% CI 1.309 – 20.127, p 
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= 0.019). Additionally, TGF-β3 (OR 1.445, 95% CI 1.023 – 2.042, p = 0.037) was associated 
with increased risk of TB recurrence in the multivariable model and a statistical trend was 
observed for TGF-β1 (OR 1.071, 95% CI 0.988 – 1.161, p = 0.097) and TGF-β2 (OR 1.210, 
95% CI 0.980 – 1.494, p = 0.076) (Table 4). Lower BMI was a significant predictor of TB 
recurrence in all the multivariable models ran. When analysed separately lower BMI was 
associated with increased risk of TB recurrence (OR 0.931, 95% CI 0.868 – 0.998, p = 
0.043). Increased risk of TB recurrence in individuals with elevated sICAM and LBP plasma 
levels likely reflect the effects of systemic inflammation and lung-gut inflammatory cross talk 
respectively. 
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 Figure 9. Plasma levels of A) LBP, B) sMAdCAM, C) sICAM, D) sVCAM, E) TGF-β1, F) 
TGF-β2 and G) TGF-β3 differentially expressed between controls (n = 103) and cases (n = 
37) in TRuTH. P-values indicated in the figures are the result of univariate conditional 
logistic regression. 
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Table 4. Univariate and multivariable analysis of TRuTH plasma analytes (sMAdCAM, 
sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3) as predictors of TB recurrence. 
1Multivariable analyses adjusted for WHO stage of the disease, BMI, lung cavities, age, CD4 count, 
VL, gender and previous history of TB.  
 
3.4 Longitudinal changes in plasma expression of measured analytes  
A small subset of cases was followed longitudinally to observe the changes in plasma 
expression of measured analytes (sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and 
TGF-β3) during active TB disease and in response to TB treatment completion. We 
compared changes in the plasma expression of measured analytes between the following 
time-points: pre-TB and TB recurrence (n = 30), TB recurrence to post TB treatment/Cure (n 
= 14) and pre-TB to post TB treatment/Cure (n = 13). Expression levels of 2 cytokines 
decreased from pre-TB time-point to active TB disease: LBP (mean difference [MD] 4.831, 
95% CI 2.693 – 6.969, p<0.0001) and sMAdCAM (MD 1.535, 95% CI 0.8862 – 2.183, 
Cytokine Univariate Multivariable1 
OR (95% CI) p-value OR (95% CI) p-value 
sMAdCAM 0.991 (0.390 – 2.520) 0.984 0.671 (0.196 – 2.305) 0.527 
sICAM 1.047 (1.014 – 1.081) 0.005 1.052 (1.012 – 1.095) 0.011 
sVCAM 1.017 (0.994 – 1.041) 0.142 1.014 (0.985 – 1.045) 0.351 
LBP 3.283 (1.018 – 10.588) 0.047 5.133 (1.309 – 20.127) 0.019 
TGF-β1 1.046 (0.973 – 1.123) 0.222 1.071 (0.988 – 1.161) 0.097 
TGF-β2 1.095 (0.930 – 1.289) 0.274 1.210 (0.980 – 1.494) 0.076 
TGF-β3 1.214 (0.951 – 1.549) 0.120 1.445 (1.023 – 2.042) 0.037 
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p<0.0001) (Figure 9A, Figure 9B respectively, Table 5), whereas TGF-β3 (MD -75.69, 95% 
CI -100.4 – 50.96, p<0.0001) levels increased (Figure 10C, Table 5). No significant 
differences were observed in measured analyte expression between active TB and post TB 
treatment/Cure time-point. From pre-TB time-point to post TB treatment (or during the entire 
follow-up), expression of 3 analytes decreased: LBP (MD 3.855, 95% CI 0.5703 – 7.139, p = 
0.0251), sMAdCAM (MD 1.153, 95% CI 0.2542 – 2.052, p = 0.0162) and sVCAM (MD 
2373, 95% CI 945.8 – 3800, p = 0.0162) (Figure 9A, Figure 9B, Figure 9D respectively, 
Table 5), whereas TGF-β3 (MD -100.4, 95% CI -128 – 72.88, p<0.0001) increased  (Figure 
10C, Table 5). Decrease in LBP, sMAdCAM and sVCAM and an increase in TGF-β3 during 
the entire longitudinal follow-up likely reflects the increased duration of ART use and the 
associated immune reconstitution.  
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 Figure 10. Longitudinal paired analysis of plasma A) LBP, B) sMAdCAM, C) sICAM and 
D) sVCAM expression at following time points: PreTB to TB (n = 30), TB to PostTB/Cure (n 
= 14) and PreTB to PostTB/Cure (n = 13). 
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Figure 11. Longitudinal paired analysis of plasma A) TGF-β1, B) TGF-β2 and C) TGF-β3 
expression at following time points: PreTB to TB (n = 30), TB to PostTB/Cure (n = 14) and 
PreTB to PostTB/Cure (n = 13 ).
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Table 5. Longitudinal paired analysis of TRuTH plasma cytokine (sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3) 
expression at following time-points: PreTB to TB (n = 30), TB to PostTB (n = 14) and PreTB to PostTB (n = 13). (Mean difference refers to 
difference in means between two timepoints)  
 PreTB - TB TB – PostTB/Cure PreTB – PostTB/Cure 
Variable N Mean difference (95% 
CI) 
p-value N Mean difference 
(95% CI) 
p-value N Mean difference (95% 
CI) 
p-value 
sMAdCAM 30 1.535 (0.8862 to 2.183) <0.0001 14 -0.6479 (-1.452 to 0.156) 0.1052 13 1.153 (0.2542 to 2.052) 0.0162 
sICAM 30 -296.2 (-1225 to 632.5) 0.5193 14 342.5 (-284.4 to 969.4) 0.2590 13 459.2 (-428.6 to 1347) 0.2818 
sVCAM 30 1440 (-1041 to 3920) 0.2448 14 1375 (-881.3 to 3632) 0.2107 13 2373 (945.8 to 3800) 0.0035 
LBP 30 4.831 (2.693 to 6.969) <0.0001 14 -0.2771 (-1.416 to 
0.8621) 
0.6081 13 3.855 (0.5703 to 7.139) 0.0251 
TGF-β1 30 -35.94 (-146.8 to 74.87) 0.5123 14 7.641 (-94.58 to 109.9) 0.8742 13 9.262 (-137.1 to 155.7) 0.8927 
TGF-β2 30 -2.673 (-31.5 to 26.15) 0.8509 14 -17.88 (-56.44 to 20.68) 0.3348 13 -13.89 (-68.17 to 40.38) 0.5872 
TGF-β3 30 -75.69 (-100.4 to -50.96) <0.0001 14 -16.4 (-56.62 to 23.82) 0.3943 13 -100.4 (-128 to -72.88) <0.0001 
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3.5 Correlation with previously measured plasma cytokines/chemokines 
Previously, Sivro et al measured the plasma expression of 23 different cytokines/chemokines 
to look at the influence they have on the risk of TB recurrence (Sivro et al., 2017). Here we 
examined if there was a correlation between the cytokines measured by Sivro et al and the 
plasma expression of sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3 
(Sivro et al., 2017). Expressions of 23 cytokines/chemokines were correlated with 
sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3 in 21 overlapping plasma 
samples. We observed a statistically significant correlation between IL-27 and sVCAM 
(r=0.438, p=0.047), IL-7 and TGF- β2 (r=0.481, p=0.027), IL-6 and LBP (r=0.623, p=0.003), 
IL-6 and TGF- β2 (r=0.438, p=0.047),  sCD14 and TGF- β1 (r=0.456 p=0.038) and sCD14 
and TGF- β1 (r=0.456, p=0.038) (Table 6).  
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Table 6. Correlation of plasma cytokines/chemokines by Sivro et al. with the measured 
analytes (sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-β2 and TGF-β3). 
Cytokines/chemokines (N=23) sMAdCAM sICAM sVCAM LBP TGF-β1 TGF-β2 TGF-β3 
IL1β r=-0.316 
p=0.162 
r= -0.299 
p= 0.188 
r=-0.057 
p=0.806 
r=0.337 
p=0.135 
r=0.123 
p=0.594 
r=0.194 
p=0.400 
r=0.305 
p=0.179 
IL1Rα r=-0.250 
p=0.274 
r= -0.346 
p= 0.124 
r=-0.049 
p=0.832 
r=0.335 
p=0.137 
r=0.068 
p=0.769 
r=0.108 
p=0.641 
r=0.220 
p=0.338 
IL2 r=0.234 
p=0.308 
r= -0.348 
p= 0.122 
r=0.216 
p=0.346 
r=0.102 
p=0.661 
r=-0.098 
p=0.672 
r=-0.151 
p=0.514 
r=-0.077 
p=0.739 
IL-6 r=-0.031 
p=0.894 
r= 0.114 
p=0.624 
r=0.264 
p=0.248 
r=0.623 
p=0.003* 
r=0.337 
p=0.136 
r=0.438 
p=0.047 
r=0.321 
p=0.156 
IL-7 r=-0.134 
p=0.563 
r=-0.342 
p=0.130 
r=0.242 
p=0.291 
r=0.273 
p=0.232 
r=0.345 
p=0.125 
r=0.481 
p=0.027 
r=0.231 
p=0.314 
IL-10 r=-0.227 
p=0.322 
r=-0.252 
p=0.271 
r=0.161 
p=0.486 
r=0.387 
p=0.083 
r=0.194 
p=0.401 
r=0.286 
p=0.209 
r=0.174 
p=0.452 
IL-15 r=0.369 
p=0.099 
r=0.369 
p=0.099 
r=0.258 
p=0.258 
r=-0.148 
p=0.523 
r=0.074 
p=0.750 
r=0.000 
p=1.000 
r=0.074 
p=0.750 
IP10 r=0.051 
p=0.827 
r= -0.273 
p= 0.232 
r=0.104 
p=0.654 
r=0.264 
p=0.248 
r=0.303 
p=0.182 
r=0.353 
p=0.117 
r=0.296 
p=0.192 
TNF-α r=-0.020 
p=0.931 
r= 0.066 
p= 0.775 
r=0.360 
p=0.109 
r=0.338 
p=0.134 
r=0.251 
p=0.272 
r=0.254 
p=0.266 
r=0.417 
p=0.060 
IL1α r=-0.057 
p=0.807 
r= 0.049 
p= 0.831 
r=0.105 
p=0.651 
r=0.105 
p=0.651 
r=-0.149 
p=0.519 
r=-0.128 
p=0.579 
r=-0.096 
p=0.680 
IL-18 r=-0.334 
p=0.139 
r=-0.255 
p=0.265 
r=-0.219 
p=0.339 
r=0.117 
p=0.614 
r=-0.010 
p=0.964 
r=0.067 
p=0.773 
r=0.141 
p=0.542 
MIG r=0.019 
p=0.933 
r= 0.062 
p=0.788 
r=-0.019 
p=0.933 
r=0.131 
p=0.571 
r=-0.145 
p=0.529 
r=-0.012 
p=0.960 
r=-0.180 
p=0.435 
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* P values that pass multiple comparisons are indicated with a star (*) 
 
 
IFN-β r=0.035 
p=0.880 
r= -0.366 
p=0.103 
r=-0.319 
p=0.158 
r=-0.313 
p=0.168 
r=-0.149 
p=0.520 
r=-0.120 
p=0.605 
r=-0.139 
p=0.548 
IFN-λ2 r=-0.316 
p=0.162 
r=-0.035 
p=0.881 
r=-0.280 
p=0.219 
r=0.106 
p=0.647 
r=-0.063 
p=0.788 
r=0.052 
p=0.822 
r=-0.109 
p=0.638 
IFN-λ1 r=0.148 
p=0.523 
r=-0.074 
p=0.750 
r=0.222 
p=0.334 
r=-0.222 
p=0.334 
r=0.111 
p=0.633 
r=0.037 
p=0.874 
r=0.037 
p=0.874 
IFN-α2 r=0.064 
p=0.782 
r=0.118 
p=0.611 
r=0.301 
p=0.184 
r=0.023 
p=0.921 
r=0.161 
p=0.487 
r=0.231 
p=0.313 
r=0.182 
p=0.429 
IFN-γ r=0.054 
p=0.816 
r=0.412 
p=0.064 
r=0.338 
p=0.133 
r=-0.184 
p=0.426 
r=-0.049 
p=0.833 
r=-0.068 
p=0.768 
r=0.047 
p=0.840 
IL-8 r=0.045 
p=0.847 
r=-0.002 
p=0.995 
r=0.007 
p=0.976 
r=0.052 
p=0.823 
r=-0.152 
p=0.509 
r=-0.170 
p=0.461 
r=-0.148 
p=0.521 
IL12p40 r=-0.265 
p=0.245 
r=-0.356 
p=0.113 
r=-0.248 
p=0.278 
r=-0.092 
p=0.691 
r=0.141 
p=0.542 
r=0.162 
p=0.483 
r=0.063 
p=0.785 
IL12p70 r=-0.243 
p=0.289 
r=-0.071 
p=0.760 
r=-0.156 
p=0.500 
r=0.000 
p=1.000 
r=-0.308 
p=0.174 
r=-0.210 
p=0.360 
r=-0.410 
p=0.065 
IL-27 r=0.258 
p=0.258 
r=0.167 
p=0.470 
r=0.438 
p=0.047 
r=0.141 
p=0.542 
r=0.088 
p=0.706 
r=-0.035 
p=0.881 
r=0.284 
p=0.213 
I-FAB r=-0.013 
p=0.956 
r=-0.065 
p=0.778 
r=0.089 
p=0.703 
r=-0.197 
p=0.392 
r=0.275 
p=0.228 
r=0.191 
p=0.406 
r=0.200 
p=0.385 
sCD14 r=-0.212 
p=0.357 
r=0.121 
p=0.602 
r=0.179 
p=0.437 
r=-0.25 
p=0.915 
r=0.513 
p=0.017 
r=0.456 
p=0.038 
r=0.418 
p=0.059 
84 
 
3.6 Changes in the expression of measured analytes from active TB disease to TB 
treatment completion in IMPRESS   
Next we followed the HIV infected (n= 38) and HIV uninfected (n = 33) participants 
longitudinally to observe the changes in plasma expression of measured analytes (LBP, 
sMAdCAM, sICAM, sVCAM, TGF-β1, TGF-β2 and TGF-β3) from active TB to post 
TB/cure. We observed no significant differences in the expression of sMAdCAM, sICAM, 
sVCAM, TGF-β1, TGF-β2 and TGF-β3 between active TB and post TB cure in HIV infected 
and HIV uninfected participants (Figure 11 B-D, Figure 12 E-G, and Table 7). A trend was 
observed towards decreased LBP in HIV uninfected participants following TB treatment 
(MD 2.026, 95% CI -0.122 to 4.174, p = 0.0638). However in HIV infected participants there 
was a trend towards higher LBP post TB cure (MD -2.081, 95% CI -4.364 toGI 0.2021, p = 
0.0726) (Figure 11A Table 7). The observed increase in LBP levels in HIV infected 
participants during follow-up is likely a result of HIV disease progression, whereas a 
decrease in LBP levels post TB cure in HIV uninfected participants could suggest that active 
TB is associated with gut inflammation and dysbiosis. 
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 Figure 12. Longitudinal paired analysis of plasma A) LBP, B) sMAdCAM, C) sICAM and 
D) sVCAM expression at active TB to Post TB/Cure in HIV infected (n = 38) and HIV 
uninfected (n = 33) participants. 
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 Figure 13. Longitudinal paired analysis of plasma A) TGF-β1, B) TGF-β2 and C) TGF-β3 
expression at active TB to Post TB/Cure in HIV infected (n = 38) and HIV uninfected (n = 
33) participants. 
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Table 7. Longitudinal paired analysis of measured analytes from active TB to post TB/cure in HIV infected (n = 38) and HIV uninfected (n = 
33) participants. 
a p-value is represented from the paired t-test 
b p-value is represented from the Wilcoxon matched-pairs signed rank test
 HIV Infected 
Active TB – Post TB/Cure 
HIV Uninfected 
Active TB – Post TB/Cure 
Variable N Mean Difference (95% CI) p-value N Mean Difference (95% CI) p-value 
sMAdCAM 38 -0.3563 (-0.9752 to 0.2626) 0.2509a 33 0.2658 (-0.22 to 0.7515) 0.2980b 
sICAM 38 905.4 (-115.6 to 1926) 0.1941b 33 -206.6 (-1201 to 788.2) 0.2798b 
sVCAM 38 1200 (-991.7 to 3392) 0.6360b 33 485.9 (-1187 to 2158) 0.7914b 
LBP 38 2.026 (-0.122 to 4.174) 0.0638 a 33 -2.081 (-4.364 to 0.2021) 0.0726 a 
TGF-β1 38 529.7 (-131.5 to 1191) 0.1365b 33 -246.5 (-959.9 to 467) 0.3483b 
TGF-β2 38 18.83 (-14.25 to 51.92) 0.3965b 33 -7.006 (-35.56 to 21.55) 0.3403b 
TGF-β3 38 10.19 (-3.399 to 23.78) 0.1612b 33 -2.42 (-13.86 to 9.019) 0.2509b 
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3.7 Changes in the expression of measured analytes between HIV infected and HIV 
uninfected individuals at active TB and following completion of TB treatment  
Finally, we wanted to characterize the effect of HIV infection on the measured analytes in 
active TB and post TB treatment subgroups. The univariate analysis revealed that the plasma 
expression of most analytes was significantly higher in HIV infected participants compared to 
HIV uninfected participants. This is expected and is likely a result of HIV induced 
inflammatory changes. At active TB time-point, it was observed that four analytes had 
significantly higher levels in HIV infected participants compared to HIV uninfected 
participants: LBP (Median 37.73, IQR 34.29 – 39.32, p = 0.04), sMAdCAM (Median 3.01, 
IQR 2.243 – 4.87, p = 0.03), sVCAM (Median 14635, IQR 10893 - 17121, p < 0.0001) and 
TGF-β2 (Median 98.96, IQR 70 – 149.5, p = 0.01) (Figure 13 A, B, D, F). At cure time-point, 
it was observed that six analytes had significantly higher levels in participants who were HIV 
infected compared to HIV uninfected participants: LBP (Median 40.28, IQR 35.38 – 43.66, p 
< 0.0001) , sICAM (Median 6245, IQR 5029 – 8046, p = 0.0084), sVCAM (Median 14530, 
IQR 10543 – 19596, p < 0.0001), TGF-β1 (Median 736.9, IQR 371.7 - 2257, p = 0.05), TGF-
β2 (Median 114.3, IQR 70.31 – 187.8, p = 0.0001) and TGF-β3 (Median 18.56, IQR 9.763 – 
58.93, p = 0.0017) (Figure 14 A, C, D, E, F, G). 
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 Figure 14. Changes in plasma expression of A) LBP, B) sMAdCAM, C) sICAM, D) 
sVCAM, E) TGF-β1, F) TGF-β2 and G) TGF-β3 between HIV infected (n = 38) and HIV 
uninfected (n = 33) individuals at active TB. 
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 Figure 15. Changes in plasma expression of A) LBP, B) sMAdCAM, C) sICAM, D) 
sVCAM, E) TGF-β1, F) TGF-β2 and G) TGF-β3 between HIV infected (n = 38) and HIV 
uninfected (n = 33) individuals following the completion of TB treatment. 
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CHAPTER 4: Discussion 
 
TB/HIV co-infection is one of the major health burdens affecting SA (Jacobson et al., 2015, 
Churchyard et al., 2014). The host inflammatory response to TB and HIV infections acts 
similarly; the initial response is needed to prevent and contain the infection, however if left 
untreated the inflammation can lead to immune mediated pathology. Previous studies have 
looked at the role of lymphocyte trafficking markers in TB and HIV respectively (Byrareddy 
et al., 2014, Byrareddy et al., 2016, Bai et al., 2018), however there continues to be a lack of 
data regarding lymphocyte trafficking markers in TB and TB/HIV co-infection.  
 
4.1 Measured analytes as predictors of TB recurrence risk in TRuTH cohort 
Here we examined if the expression of sMAdCAM, sICAM, sVCAM, LBP, TGF-β1, TGF-
β2 and TGF-β3 had an effect on the rate of TB recurrence. In the univariate and multivariable 
logistic model, the risk of TB recurrence was significantly associated with increases in the 
plasma expression of sICAM and LBP, known to play a role in inflammation and microbial 
translocation respectively. ICAM is present on endothelial cells and its expression is 
increased by pro-inflammatory cytokines (Wolf, 2009). ICAM is involved in the firm arrest 
and transmigration of leukocytes from blood vessels to tissues (Lawson and Wolf, 2009). 
Previous studies have shown that the concentration of sICAM is elevated in patients with 
active TB disease (Lai et al., 1993). A decrease in ICAM levels was observed in response to 
anti-TB treatment suggesting that the serum concentration of sICAM is linked to bacterial 
activity (Demir et al., 2002, Ramirez et al., 1994, Lai et al., 1993, Mukae et al., 2003). Our 
data supports these findings. Increase in sICAM prior to TB disease observed in our study 
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likely reflects increased systemic inflammation as a result of increased bacterial replication 
and activation of latent disease.  
 
In serum, LBP is present as a soluble acute-phase protein which binds to LPS and stimulates 
an immune response by presenting the LPS to important cell surface PRRs such as CD14 and 
TLR4. Increased concentrations of LBP have been observed in patients with sepsis and in 
healthy individuals injected with LPS (Froon et al., 1995, van der Poll et al., 1997). A study 
conducted by Juffermans et al. showed that levels of LBP was elevated in individuals with 
active TB and declined during treatment, suggesting that LBP may have importance in the 
host reaction to TB (Juffermans et al., 1998). Increased levels of plasma LBP were associated 
with an increased risk of TB recurrence in this study. Since the TRuTH cohort only includes 
HIV co-infected individuals, increased LBP levels likely reflect the HIV induced microbial 
translocation as well as TB bacterial activity. There was a strong positive correlation between 
LBP and IL-6 measured by Sivro et al. IL-6  was one of the main pro-inflammatory cytokines 
associated with TB recurrence in the previous study (Sivro et al., 2017). Interestingly, LPS 
was shown to be a strong inducer of IL-6 and ICAM-1 suggesting that HIV associated 
microbial translocation could be the main driver of inflammation, driving the increased risk 
of TB recurrence (Sawa et al., 2008). Dysbiosis of the gut microbiota due to HIV is known to 
cause systemic inflammation and as a result can lead to opportunistic infections including 
TB. Furthermore gut inflammation can be linked to lung inflammation, since 50% of adults 
who suffer with IBD and 33% of individuals who suffer with IBS have pulmonary 
involvement (Yazar et al., 2001, Keely et al., 2012). This likely indicates that there is an 
inflammatory cross talk between different mucosal sites and that inflammation and dysbiosis 
in the gut can lead to inflammatory changes in the lungs (Budden et al., 2017, Brenchley et 
al., 2006b). 
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After adjusting for covariates, the risk of TB recurrence was associated with increased 
concentrations of TGF-β3 and although not statistically significant, there was a statistical 
trend toward increased concentration of TGF-β1. TGF-β belongs to a superfamily of 
cytokines which include three isoforms; TGF-β1, TGF-β2, and TGF-β3 (Morikawa et al., 
2016). TGF-β is involved in enhancing regulatory T cell responses and having stimulatory 
and inhibitory effects on various cell types (Nathan and Sporn, 1991, Yano et al., 2012). 
Previous studies have reported that the production of TGF-β by monocytes and DCs is 
induced by mycobacterial products and as a result TGF-β is produced in excess during active 
TB and at the site of infection (Toossi et al., 1995, Condos et al., 1998).  Excess TGF-β was 
shown to supress T cell responses to M.tb antigens (Hirsch et al., 1997). These studies 
corroborate our findings, in that expression of TGF-β was elevated prior to active TB disease 
and likely reflects increased bacterial activity. Additionally, TGF-β1 and TGF-β2 expression 
was shown to positively correlate with sCD14 expression. It has previously been shown that 
active TB is associated with plasma sCD14, a known marker of monocyte activation (Sandler 
et al., 2011).  
 
Additionally, the risk of TB recurrence was significantly associated with a low BMI in our 
study. The effect of BMI on the risk of TB has been examined previously (Tverdal, 1986, 
Leung et al., 2007, Lönnroth et al., 2009b). There has been a consistent and strong log-linear 
relationship between the incidence of TB and BMI in different settings (Lönnroth et al., 
2009b). In a South African HIV infected cohort, HIV infected individuals with high BMI had 
a significantly reduced risk of mortality and TB after adjusting for HAART and CD4 count 
(Hanrahan et al., 2010). Our data agrees with these findings showing that low BMI is 
associated with increased risk of TB likely due to impairment of the immune system, as a 
result of malnutrition. 
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4.2 Effect of active TB and treatment completion on analyte expression in TRuTH 
We looked at the longitudinal changes in plasma expression of the measured analytes from 
prior to TB reactivation (pre-TB), during active TB disease and post TB treatment/cure. It 
was found that three analytes (LBP, sMAdCAM and TGF-β3) had significant differences 
between pre-TB and active TB disease time-points. Between pre-TB and active TB disease 
there was a decreased concentration of LBP and sMAdCAM and an increased concentration 
of TGF-β3. No differences were observed in the measured analytes between active TB 
disease and post TB treatment/cure time-points. Moreover, there was a significant decrease in 
the expression levels of LBP, sMAdCAM and sVCAM and a significant increase in the 
expression level of TGF-β3 between pre-TB and post TB/cure time-points (or during the 
whole follow-up). The lack of differences between active TB disease and post treatment 
completion time-points suggest that the observed changes in the analyte expression during 
follow-up are likely a result of increased ART duration and HIV disease progression rather 
than a direct effect of TB disease activity (Papasavvas et al., 2008). 
 
A study by Feng et al. showed that M.tb infection induces the upregulation of VCAM-1 on 
pulmonary endothelium in mice with no changes in sMAdCAM (Feng et al., 2000). sVCAM 
is a marker of vascular inflammation and plays a major role in leukocyte recruitment (Carlos 
and Harlan, 1994). A study by Lai et al. found increased expression of circulating VCAM-1 
during active TB disease and this could be a mechanism in which the inflammatory 
leukocytes are attracted to the site of the lesion leading to the development of the disease (Lai 
et al., 1993). A study conducted by Sharma et al. found increased concentrations of VCAM-1 
at active TB disease, as well as after completing TB treatment, proposing that VCAM-1 is 
important in maintaining the lymphocytic inflammation in the lungs (Sharma et al., 1992, Lai 
et al., 1993). We did not observe any changes in sVCAM expression with active TB disease 
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with an overall  decrease in concentrations of sVCAM and sMAdCAM during the entire 
study follow-up likely reflecting the effect of ART duration and decreased inflammation 
(Papasavvas et al., 2008).  
As with sVCAM and sMAdCAM we observed an overall decrease in plasma LBP expression 
during the study follow-up. ART was previously shown to lead to decreased plasma LBP 
levels (Nyström et al., 2015) and this is likely reflected by our data.  
 
Previous studies have reported increased concentrations of TGF-β in individuals with 
pulmonary (Dlugovitzky et al., 2000)  and severe TB (Fiorenza et al., 2005). Here we 
observed an increase in TGF-β3 between pre-TB and active TB time-point as well as an 
overall increase during the entire follow-up. While the initial increase might, to some degree, 
reflect the increased bacterial activity and active TB disease, TGF-β levels  are known to 
increase steadily during HIV infection irrespective of ART (Wiercińska-Drapalo et al., 2004). 
This sustained elevation in circulating TGF-β despite ART treatment is thought to contribute 
to immunosuppression and progression to AIDS, even in virally supressed individuals 
(Theron et al., 2017).  
 
4.3 Effect of active TB and treatment completion on analyte expression in IMPRESS 
Next, we examined the changes in the expression of LBP, sMAdCAM, sICAM, sVCAM, 
TGF-β1, TGF-β2 and TGF-β3 from active TB disease to TB treatment completion in HIV 
infected and HIV uninfected individuals from IMPRESS. No significant differences was 
observed in the expression of sMAdCAM, sICAM, sVCAM, TGF-β1, TGF-β2 and TGF-β3 
between active TB disease and post TB treatment/cure in HIV infected and HIV uninfected 
individuals. Although not statistically significant, there was a trend towards decreased 
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concentrations of plasma LBP in HIV uninfected individuals following TB treatment. This 
potentially suggests that active TB is associated with inflammation of the gut that is resolved 
by successful treatment completion. A trend towards increased concentrations of plasma LBP 
was observed in HIV infected individuals following TB treatment, likely reflecting a decrease 
in the gastrointestinal integrity caused by progressing HIV infection (Funderburg et al., 2013, 
Brenchley et al., 2006b).  
 
As expected plasma expression of majority of the measured analytes was increased in HIV 
infected individuals at active TB disease and post TB treatment time-points. HIV infection is 
known to increase the plasma expression of LBP (Ancuta et al., 2008), sMAdCAM (Miao et 
al., 2002), sICAM (Mastroianni et al., 2000), sVCAM (Graham et al., 2013) and TGF-β 
(Tudela et al., 2014) contributing the overall chronic immune activation and disease 
progression. 
 
Interestingly, we did not observe any differences in the measured analyte expression between 
males and females. Previous research has shown that males are more affected by TB 
compared to females, with a case notification of 2:1 (Neyrolles and Quintana-Murci, 2009). 
These gender differences can be due to both biological (such as hormone and immune 
differences) (Borgdorff et al., 2000, Blaak, 2001, Salim et al., 2004, Kolappan et al., 2007, 
Boelaert et al., 2007) as well as social (such as access to care and work 
environment)(Lönnroth et al., 2009a, Lönnroth et al., 2010, Hargreaves et al., 2011) aspects. 
The process of case-notification is complicated and ultimately combines a number of factors 
such as: (i) difference in susceptibility and exposure, (ii) access to healthcare services and 
(iii) help seeking behaviour (Neyrolles and Quintana-Murci, 2009). Although some reviews 
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have suggested that under-notification of women in developing countries could be due to 
access to clinics, timely diagnosis or treatment and sex bias could be major influences on the 
rate of TB (Gordon and Rylance, 2009, Lönnroth et al., 2008, Lienhardt et al., 2005, Khan et 
al., 2007). Therefore, it is likely that case notifications may not reveal the number of aspects 
between sexes and TB susceptibility (Neyrolles and Quintana-Murci, 2009). A case-control 
study conducted by Lienhardt et al found that male sex was a TB risk factor and was 
independent of other behavioural factors studied (Lienhardt et al., 2005). Even with income, 
awareness and stigma accounted for, a survey conducted revealed that confirmed TB was 
seen 3 times more in males ass compared to females (Borgdorff et al., 2000, Salim et al., 
2004). Men are more susceptible to pulmonary TB based on specific biological sex factors 
such as: sex hormones, sex chromosomes and sex specific metabolic features (Neyrolles and 
Quintana-Murci, 2009, Klein and Flanagan, 2016). It can be seen from the IMPRESS cohort 
characteristics that active TB individuals that are HIV uninfected are predominantly males 
(31 males vs 6 females). The ratio of males to females with active TB changes in HIV 
infected IMPRESS and TRuTH cohort, and this is likely due to HIV infection. Young women 
in SA are at high risk of HIV infection, and once infected become at high risk of TB. 
Additional studies are needed to fully understand the immunological aspects of gender 
differences in TB susceptibility.   
 
Study limitations and future directions 
Our study could be improved in several ways. To expand this study and increase our 
understanding of lymphocyte trafficking in TB and TB/HIV co-infection, cell phenotyping 
looking at the cell surface integrins should be conducted. Ideally this should be done in 
mucosal samples including gut and lung tissues. Unfortunately at the time of the study we did 
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not have access to additional sample types such as matching PBMCs and mucosal samples. 
Additionally the study design did not include non-HIV infected and non-TB infected samples 
for comparison to “normal” plasma analyte levels. Microbiome analysis of the gut and lung 
mucosa should also be performed to look at the dysbiosis and gut-lung axis in TB/HIV co-
infected individuals.  
 
Future studies could also examine matched BAL and plasma samples in different and larger 
cohorts in order to identify and validate immune activation markers that could be used for 
development of a rapid point of care device to predict active TB. 
 
Conclusion 
Here we identified increased expression of plasma LBP and sICAM as predictors of TB 
recurrence in individuals who were receiving ART treatment in the TRuTH cohort. A trend in 
decreased levels of plasma LBP from active TB disease to treatment completion in HIV 
uninfected individuals from IMPRESS, could provide evidence that active TB and the 
associated inflammatory changes could lead to gut inflammation and dysbiosis. Increased 
plasma LBP in HIV infected individuals following the completion of TB treatment in 
IMPRESS cohort likely reflects gut damage and microbial translocation, as a result of HIV 
disease progression. This study has important implications in providing insight into the role 
of lymphocyte trafficking and inflammation markers in TB and TB/HIV co-coinfection.  
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